Trading Analysis Report: MCD¶

Analysis date: 2026-10-21
Rating: Hold
Generated: 2026-10-21 12:57:57
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 245.28 Price As Of: 2026-10-21

MCD (McDonald's Corporation, NYQ): Technical Report as of 2026-10-21¶

1. Data integrity note¶

The verified snapshot, which I'm treating as the source of truth, shows a 2026-10-21 close of 245.28 on volume of 2,565,906.
The raw get_stock_data feed shows 245.16 on volume of 2,565,335 for the same date. The gap is small but real, and I haven't reconciled it.
That volume is well below the 4–6M typical of recent sessions. The 10/21 bar may therefore be an incomplete or intraday print, which is my inference and isn't confirmed by the tools.
Treat every 10/21-dependent reading (RSI, MACD, Bollinger, z-score, TD count) as provisional until the bar finalizes.

2. Big picture: a sharp bear leg followed by a relief rally¶

Figures below come from the price series.

Prior uptrend: MCD climbed from about 287 in early October 2025 to a closing high of 334.50 on 2026-02-27. The intraday high that window was 335.18 on 03-02.
Decline: The stock then fell almost without interruption. There were three notable waves down:
March: 321.81 on 03-17 to about 304 by 03-20.
Late April to early May: about 295 to about 271 by 05-08.
September: 261 to 230.94 on 09-30.
Capitulation-style day: On 2026-09-23 the stock fell from 250.35 to 238.32 (about -4.8%) on 16.6M shares, the heaviest volume in the dataset. The tools don't say why, so I won't speculate on the catalyst.
Low: The lowest close was 230.88 on 10-07. The intraday low was 229.20 on 10-05.
Peak-to-trough: About -31% on a closing basis, from 334.50 to 230.88.
Bounce: The stock is now at 245.28, about +6.2% off the closing low and still about 26.7% below the February closing high.
Reversal volume: On 10-08 the stock rose from 230.88 to 236.90 (about +2.6%) on 11.36M shares. That is a high-volume reversal day, and it marked the start of the bounce.

3. Trend structure: the higher timeframes are still bearish¶

SuperTrend (14, 3x ATR), three timeframes

Tier	Direction	Trailing stop	Close vs. stop
Weekly (primary)	DOWN	265.86	-7.74%
Monthly (regime)	DOWN	306.43	-19.95%
Daily (entry timing)	UP	232.28	+5.60%

The tool says to weight higher tiers over lower ones. The weekly and monthly trends are down, and only the daily has flipped up.
This is a daily counter-trend rally inside a weekly and monthly downtrend.
A weekly close above 265.86 would be the first higher-tier evidence of a trend change. That is about +8.4% from here.
The daily stop at 232.28 is the nearest trailing-risk line. It sits just above the 10-07 closing low of 230.88.

Moving averages (verified) - 10 EMA: 241.24. Price is above it, which is short-term constructive. - 50 SMA: 250.18. Price is about 2.0% below it. - 200 SMA: 282.01. Price is about 15% below it, and the average is still falling. It went from 289.48 on 09-21 to 282.01 on 10-21. - The 50 SMA is below the 200 SMA, a bearish long-term configuration. The 200 SMA is still declining, so there is no sign of long-term trend repair.

4. Momentum: a strong rebound from deeply oversold, with the move maturing¶

RSI (14) - The latest reading is 55.61, down from 58.18 on 10-20. - RSI was below 30 for 11 consecutive sessions, from 09-23 through 10-07. It bottomed at 21.78 on 09-30. - It reclaimed 50 on 10-15 and has stayed above it. - That is a full oversold-to-neutral reset. It is not overbought, so RSI does not argue against further upside. - RSI has risen from the bottom without yet testing the 70 area. In a downtrend, RSI rallies often stall in the 55–65 zone, which is worth watching.

MACD histogram - The histogram has been positive since 10-08 (+0.28). The latest value is +2.31, versus +2.33 on 10-20. - The MACD line is -1.34, still below zero, and the signal line is -3.65. - The bullish crossover is intact, but both lines are below zero. That is typical of a relief rally and not a confirmed trend reversal. - The histogram has flattened over the last two sessions, so momentum gains are plateauing.

5. Volatility and risk¶

ATR: 4.31, about 1.76% of price. It peaked at 5.12 on 09-24 and has been compressing as the sell-off calmed.
Bollinger Bands (verified):
Upper band 246.41, middle 236.70, lower 226.99.
Price is 1.13 below the upper band, which puts it near the top of the band range.
The distance from the upper band to the lower band is 19.42.
ATR-based stop references (arithmetic):
2x ATR below the close is about 236.66, close to the Bollinger midline at 236.70.
3x ATR below is about 232.35, close to the daily SuperTrend stop at 232.28.
Those two overlaps give natural risk levels for a long idea.

6. Volume and participation¶

OBV: The latest reading is -34.76M. It fell to -73.34M on 09-30 and has recovered strongly.
OBV is now above where it was on 09-22 (-37.11M), when price was higher at 250.35. In other words, OBV has fully retraced the late-September drop while price has recovered only about 74% of that drop. That is a mildly constructive divergence, meaning volume flow has recovered faster than price.
OBV is still deeply negative on a longer view. Absolute levels aren't meaningful, but this fits a bounce within a larger distribution phase.
Bounce-day volumes of 5–7M show real participation. Several sessions in the rally had above-average volume.
The partial 10/21 volume prevents a read on today's participation.

7. Stretch and exhaustion: conflicting signals across timeframes¶

Z-score (20-period)

Tier	Reading	Interpretation
Weekly	-0.95	Near the mean
Monthly	-1.78	Below the mean, approaching the -2 stretch threshold
Daily	+1.77	Stretched above the mean, approaching +2

TD Sequential setup

Tier	Count	Interpretation
Weekly	-1	Sell-setup just beginning (1 of 9)
Monthly	+7	Buy-setup 7 of 9, approaching a downside exhaustion signal
Daily	-9	Sell-setup complete, a short-term upside exhaustion watch

A quick read of the closes fits the daily sell-setup. Closes from 10-08 through 10-21 each sit above the close four bars earlier, and the tool reports the count at 9.
Daily: The stock has moved far and fast. A completed daily 9, a +1.77 z-score and a price near the upper Bollinger Band all point to a stretched short-term bounce. That favors a pause or pullback, but none of these signals is a confirmed reversal.
Monthly: A buy-setup at 7 of 9 together with a -1.78 z-score suggests selling pressure is maturing on the longest timeframe. The monthly count would need two more monthly bars to complete, so this is a months-long watch and not an imminent signal.
Weekly: This is the primary tier and it is neutral, with a z-score near the mean and a TD count of only -1. It gives no strong timing edge either way.

8. Reference levels (derived from verified values and dated closes)¶

Overhead - 246.41: upper Bollinger Band, +0.5%. - 250.18: 50 SMA, +2.0%. It sits near the 250.35 close on 09-22, the last close before the 09-23 breakdown. - 257.49: the 09-14 close, a local peak before the late-September drop, +5.0%. - 265.86: weekly SuperTrend stop, +8.4%. - 282.01: 200 SMA, +15.0%.

Below - 241.24: 10 EMA, -1.65%. - 236.70: Bollinger midline, -3.5%. - 232.28: daily SuperTrend stop, -5.3%. - 230.88: closing low on 10-07. - 229.20: intraday low on 10-05. - 226.99: lower Bollinger Band.

I haven't validated any of these as support or resistance from past reactions. They are reference levels only.

9. Scenario framework¶

Bullish continuation:
Price clears 246.41 and then 250.18, and the daily SuperTrend stays up.
OBV keeps rising and the MACD histogram re-expands.
Confirmation of a larger trend change would be a weekly close above 265.86.
A 250–257 retest becomes the first meaningful test of whether the bounce has legs.
Consolidation or pullback (the base case on short-term signals):
The daily TD 9, the daily z-score of +1.77 and the plateauing MACD histogram all point to a pause.
A pullback toward the 10 EMA at 241.24 or the midline at 236.70 would be ordinary behavior for a bounce of this size.
Holding above 232.28 would keep the daily uptrend intact.
Bearish resumption:
A close below 232.28 would flip the daily SuperTrend back down.
A move back under the 230.88 closing low would put the 226.99 lower band in play.
The weekly and monthly trends already favor this path.

10. Summary read¶

The higher timeframes (weekly and monthly SuperTrend, falling 200 SMA, 50 SMA below 200 SMA) are firmly bearish. A strong, volume-supported oversold bounce is underway on the daily chart. It is now stretched by several short-term measures (daily TD 9, +1.77 daily z-score, price near the upper band). On the longer view, the monthly z-score of -1.78 and the 7 of 9 monthly buy-setup hint at maturing downside exhaustion, but it is early. The weekly tier is neutral. For risk, a 2–3x ATR stop sits around 232–237, and the daily SuperTrend at 232.28 lines up with the 3x ATR stop.

11. Summary table¶

Category	Indicator	Latest value	Reading
Price	Close (verified)	245.28 (2026-10-21)	About +6.2% off the 230.88 closing low and about -26.7% from the 334.50 closing high
Data check	Feed vs. snapshot	245.16 vs. 245.28	Small discrepancy, flagged; the 10/21 bar may be partial
Trend	SuperTrend weekly	DOWN, stop 265.86	Primary trend bearish; close 7.74% below stop
Trend	SuperTrend monthly	DOWN, stop 306.43	Regime bearish
Trend	SuperTrend daily	UP, stop 232.28	Counter-trend bounce; 5.60% above stop
Trend	10 EMA	241.24	Price above; short-term constructive
Trend	50 SMA	250.18	Overhead, about 2.0% above price
Trend	200 SMA	282.01	Falling; price about 15% below
Momentum	RSI	55.61	Recovered from 21.78 on 09-30 and above 50 since 10-15; neutral
Momentum	MACD histogram	+2.31	Positive since 10-08 but flattening; MACD line -1.34 below zero
Volatility	ATR	4.31 (about 1.76%)	Down from 5.12 on 09-24; compressing
Volatility	Bollinger Bands	226.99 / 236.70 / 246.41	Price near the upper band
Volume	OBV	-34.76M	Recovering from -73.34M on 09-30; mildly constructive divergence vs. price
Stretch	Z-score (W / M / D)	-0.95 / -1.78 / +1.77	Weekly neutral; monthly leaning oversold; daily stretched high
Exhaustion	TD-9 (W / M / D)	-1 / +7 / -9	Daily sell-setup complete (pullback watch); monthly buy-setup building
Key resistance refs	—	246.41, 250.18, 257.49, 265.86, 282.01	Reference levels, not validated
Key support refs	—	241.24, 236.70, 232.28, 230.88, 226.99	Reference levels, not validated
Overall	—	—	Higher timeframes bearish; daily bounce stretched; weekly neutral

Sentiment Analyst¶

Overall Sentiment: Mixed (Score: 5.2/10) Confidence: Low

Scope and data limits (MCD, 2026-10-14 to 2026-10-21). Reddit was disabled by configuration, so one of the three sources is absent. The news feed has 18 headlines with no article bodies, so only titles and framing can be read. StockTwits has 30 messages, of which only 9 carry a user sentiment tag. No price, volume, options-flow or verified analyst data was provided beyond what retail users quote. Confidence is therefore low.

1. Source-by-source breakdown

News (Yahoo Finance, 18 headlines, institutional framing). Eight headlines name MCD or McDonald's directly. They split roughly evenly: 3 cautious, 3 constructive, 2 neutral. The rest are peer, macro or dividend-list pieces. - Cautious on fundamentals: 'Can MCD's Menu Innovation Offset Slower U.S. Comparable Sales Growth?' (Zacks), 'How Softer U.S. Sales Will Impact McDonald's Stock Investors' (Simply Wall St.), and 'ETFs Are Net Sellers of McDonald's (MCD) on Oct. 19' (GuruFocus). Together these point to softening U.S. comps and modest passive outflows. The headlines alone do not show how large either is. - Constructive on price, valuation and income: 'McDonald's (MCD) Rises Higher Than Market' (Zacks), 'Is The Market Underpricing McDonald's Stock?' (Trefis), and '3 Reasons to Own McDonald's Stock by Dec. 1 to Qualify for Its First Payout as a Dividend King' (Motley Fool). Two further dividend-income roundups ('These 2 Dividend Stocks Are Money-Printing Machines' and '3 Restaurant Stocks That Turn Burgers, Pizza and Pasta Into Dividend Income') may or may not feature MCD, which cannot be confirmed from the titles. - Neutral, event-driven: the WSJ piece 'Goldman, McDonald's, Microsoft Push Back Against Efforts to Tokenize Their Stocks', echoed by Decrypt and Unchained (objections reportedly at 16 companies), and 'McDonald's (MCD) Is Considering A Tech Led Transfer Of Its Israel Franchise' (Simply Wall St.). Neither has an obvious near-term price implication from the headline. - Context pieces: 'The drive-thru is becoming a splurge like never before' (TheStreet) is an affordability and pricing-power angle. Macro headlines ('Inflation Is Back. Is A Stock Market Crash Next?', 'Which Stocks Are Paying For $4.33 Gas?') are a consumer-spending headwind. Peer items cover Chipotle, Starbucks' FY27 tech overhaul and Pepsi.

StockTwits (30 most recent messages, Oct 20-21). The user-tagged split is 6 Bullish (20%) and 3 Bearish (10%), with 21 unlabeled. That is 2:1 bullish, but on only 9 labeled posts it is not a statistically meaningful ratio. Tag quality is also weak: - Several bullish tags are product anecdotes: 'my wife likes the Diet Coke' and 'MCD coke is the best'. - One bullish tag (@Slippery_Steve) is bullish on $SPCX and calls MCD, HD and NKE 'losers', so it is effectively negative on MCD. - One bullish tag (@TooMuchMoneyBurning) is mainly an NFLX call that mentions MCD, claiming MCD rose 'straight up' after an earnings crash. That is an unverified inference that MCD fell after a recent earnings report. - Genuinely MCD-bullish tags are about two: 'best setup in the market right now' and 'stayed above the trend line, lets see what it does around 250'. - The three bearish tags are mostly anecdotal: a 'NcDonalds' sign in Pensacola, 'not paying money on tap water', and the only price-related one, 'gave it all up in overnight'.

Unlabeled content: - Constructive: a call for $270 by end of week, one user entering MCD alongside an NFLX entry, a promotional options bot quoting $245.68 with Nov 13 $245 calls (a sales post, not independent signal), and a remark that MCD is 'up 1.5%' and 'propping up the index'. - Skeptical: 'rigged market / market maker EOD dump for options expiring', 'dying companies: $NKE $MCD', and '$5 for a large fry? ... bring them to their knees'. The last is a consumer value backlash. - One user, @mama2024, accounts for 5 of the 30 messages. They reference a Citi Buy rating with the price target cut to $295 and say they are buying more. This is retail hearsay, not corroborated in the news feed, but if accurate it implies about 20% upside to target from about $245 with a Buy rating kept. - Technical chatter is mixed: 'gap could still fill' (direction ambiguous), 'looks like a dog with fleas ... scratching support/resistance', and an Elliott Wave promo citing wave (I) at $341.78 with an odd reversal zone of $209.92-$162.37. That last post is unverifiable and internally hard to reconcile, so I give it little weight.

Reddit. Not available (disabled). There is no read from r/wallstreetbets, r/stocks or r/investing, and nothing should be inferred about them.

2. Cross-source divergences and alignments - Alignment on affordability: TheStreet's 'drive-thru splurge' framing and the StockTwits '$5 large fry' complaint both point to price perception as a live issue. This is consistent with the headlines on slower U.S. comps. - Alignment on near-term price action: Zacks ('rises higher than market') and StockTwits ('up 1.5%', 'propping up the index') both describe relative strength around Oct 20. StockTwits then describes a fade (an overnight give-up and an EOD dump on Oct 21), so the move was not clearly sustained. - Divergence in tone: news leans cautious on fundamentals (comps, ETF selling) but positive on valuation and dividends. Retail is more tactical and dip-buying (levels of 250 and 270, calls) and more bullish on price than the fundamentals headlines suggest, though the evidence is thin and partly promotional. - Relative positioning: retail posts group MCD with laggards (NKE, HD) as 'losers' or 'dying companies'. Others cite MCD as a holding that is up, so the group is split on whether MCD is a laggard or a relative winner. - Net: the sources point in different directions without a decisive edge, which supports Mixed rather than a directional label.

3. Dominant narrative themes 1. Slowing U.S. comparable sales versus menu innovation and value offerings. This is the main fundamental debate in the news. 2. Consumer affordability and pricing fatigue, in both news and retail chatter, set against macro worries (inflation, $4.33 gas). 3. Defensive income appeal: Dividend King status and the Dec. 1 holding-date hook. 4. Tokenized-stock pushback, a governance and market-structure story that includes McDonald's. It is probably low-impact on sentiment. 5. Short-term technical and options-expiry positioning ($245-$250 support area, $270 hopes, EOD fade, gap-fill talk).

4. Catalysts and risks surfaced by the data - Catalysts: the dividend-eligibility date around Dec. 1 (possible income-driven demand); valuation arguments ('market underpricing'); a reported Citi Buy with a $295 target (unverified); menu and value innovation; the pending Israel franchise tech-led transfer (low materiality). - Risks: continued U.S. comp softness; consumer pushback on price and value; ETF net selling (Oct 19); macro and inflation-driven consumer weakness and broader market drawdown fears; a target cut (even with a Buy rating) that may cap momentum; intraday fades and options-expiry volatility. Retail posts show frustration but no coordinated bearish campaign. - Data gaps: no earnings date or results, price or volume data, or analyst notes were provided. The StockTwits sample is small and one user is overrepresented. Reddit is missing.

5. Summary of key sentiment signals

Signal	Direction	Source	Supporting evidence
Slower U.S. comps	Bearish	News (Zacks, Simply Wall St.)	'Slower U.S. Comparable Sales Growth' and 'Softer U.S. Sales' headlines
ETF flows	Mildly bearish	News (GuruFocus)	'ETFs Are Net Sellers of MCD on Oct. 19'
Relative strength	Mildly bullish	News (Zacks), StockTwits	'Rises Higher Than Market'; 'up 1.5%'; 'propping up the index'
Valuation and dividend appeal	Bullish	News (Trefis, Motley Fool)	'Market Underpricing MCD?'; Dividend King payout by Dec. 1
Tokenization pushback	Neutral	News (WSJ, Decrypt, Unchained)	MCD among objectors; no direct earnings link
Retail tagged ratio	Mildly bullish, low quality	StockTwits	6 Bullish / 3 Bearish / 21 unlabeled of 30; several tags are product anecdotes or off-ticker
Retail price targets and levels	Mildly bullish	StockTwits	$270 hope, 250 trend line, $245.68 quote with Nov 13 $245 calls (promotional)
Retail fade and rigging complaints	Mildly bearish	StockTwits	'gave it all up overnight', 'EOD dump', 'gap could still fill'
Affordability backlash	Bearish	StockTwits, News (TheStreet)	'$5 for a large fry'; 'drive-thru splurge'
Analyst action (unverified)	Mixed	StockTwits (@mama2024)	Citi reportedly Buy, target cut to $295
Macro consumer risk	Bearish	News (Trefis)	'Inflation Is Back', '$4.33 gas'
Reddit	No data	Reddit	Disabled by configuration

Overall: news is balanced between cautious fundamentals and supportive valuation and dividend framing, and retail is modestly constructive but low in quality and volume. This is signal for the trader to weigh alongside fundamentals and technicals, not a price call.

News Analyst¶

MCD (McDonald's Corporation, NYSE) — Weekly News and Macro Report, 2026-10-14 to 2026-10-21¶

Data coverage¶

FRED macro data failed. Every call returned DATA_UNAVAILABLE (fed funds, CPI, unemployment, 10-year Treasury, VIX, using both friendly aliases and raw IDs like FEDFUNDS and DGS10). I have no verified figures for rates, inflation, yields, or labor, and I haven't estimated any.
News was headline-only. I got titles and sources, with no article text. Anything below about sales figures, guidance, or earnings is inferred from headlines and isn't confirmed.
The 10-01 to 10-14 MCD news pull returned nothing. The tool said Yahoo only samples recent articles, so this doesn't mean there was no news.
Prediction markets did return data, and it's the only quantitative macro evidence in this report.

1. MCD company news¶

Soft U.S. same-store sales is the main theme. - Three headlines point the same way: "Can MCD's Menu Innovation Offset Slower U.S. Comparable Sales Growth?" (Zacks), "How Softer U.S. Sales Will Impact McDonald's Stock Investors" (Simply Wall St.), and a Trefis piece asking whether the market is underpricing the stock. - The framing suggests U.S. comps have decelerated and the debate is whether menu innovation can offset that. I couldn't verify the comp number, the quarter, or whether this follows a recent earnings print, so check the latest earnings release.

Pricing and value. - TheStreet ran "The drive-thru is becoming a splurge like never before." It suggests average check sizes keep rising, which fits a value-perception problem for quick-service restaurants (QSR). - That could pressure traffic among lower-income customers. It's a theme to watch, not a confirmed MCD data point.

Dividend catalyst. - Motley Fool's headline, "3 Reasons to Own McDonald's Stock by Dec. 1 to Qualify for Its First Payout as a Dividend King," points to a dividend date around Dec. 1. - It implies MCD is reaching Dividend King status (50 consecutive years of dividend increases). Confirm the exact record and ex-dividend dates against the company's announcement. - Dividend-oriented retail demand, as in the "money-printing machines" and "restaurant stocks for dividend income" pieces, can support the stock when the market is uncertain.

Flows. - GuruFocus reported ETFs were net sellers of MCD on Oct. 19. This is a minor, short-term flow signal. - Zacks noted MCD "rises higher than market" on a recent session, so price action was mixed with no clear trend.

Tokenized-stock pushback. - WSJ reported that Goldman Sachs, McDonald's, and Microsoft are pushing back against third parties tokenizing their stocks. Unchained reported objections had reached 16 companies, and that Microsoft and Alphabet barred their tokenized shares from the OKX-ICE venue. - This is governance and brand-control news. It's very unlikely to affect earnings.

Israel franchise. - Simply Wall St. reports MCD is considering a tech-led transfer of its Israel franchise. This is a small, strategic item and not financially material on its own.

Peers. - Chipotle: "What Are Chipotle Investors Betting On?" (Trefis). - Starbucks: an FY27 tech overhaul aimed at margins (Zacks). - Pepsi: "in bigger trouble than you think" (24/7 Wall St.). - Taken together, the consumer-facing food and beverage space is under scrutiny for slowing demand and margin pressure.

2. Macro and cross-asset context¶

What the headlines say (unverified, no data behind it): - Trefis ran "Which Stocks Are Paying For $4.33 Gas?" and "Inflation Is Back. Is A Stock Market Crash Next?" - If gasoline is around $4.33 a gallon, that is a headwind for QSR. Low- and middle-income consumers, who are core to MCD's traffic, lose discretionary spending, and delivery and logistics costs go up. - WSJ reported "Gold Futures Edge Up as Oil Prices Slip," so oil was easing at the margin. I have no level or trend data to size this. - Pre-market news pointed to stocks rising ahead of Meta and Tesla earnings, and IBM and Palantir previews were also in the news. Market attention is on AI and mega-cap tech earnings, not defensives.

Prediction markets (Polymarket):

Market	Implied probability	Volume
No Fed rate cuts in 2026	97%	~$9.0M
US recession by end of 2026	8%	~$2.3M
US inflation >4.5% in 2026	16%	~$232K
US inflation >5% in 2026	8%	~$342K
US inflation >6% in 2026	3%	~$70K

Rates: The market sees almost no chance of further Fed cuts in 2026. This is the deepest and most reliable market in the set. It implies "higher for longer" with no rate relief this year, which matters for valuation of long-duration, bond-proxy stocks like MCD.
Recession: At 8%, the market sees a soft landing as the base case. It isn't pricing a demand shock, though the QSR sales slowdown suggests consumer weakness is uneven.
Inflation: The tails are thin (16% for above 4.5%, 8% for above 5%), but the "inflation is back" headlines show the topic is live. I don't know which measure these markets resolve on, so I wouldn't read the exact levels too literally.
Oil: There were no matching prediction markets.

3. Implications for MCD¶

Positives - MCD is a defensive, dividend-reliable name. The Dividend King milestone and the roughly Dec. 1 dividend date could attract income buyers. - A low recession probability (8%) is supportive for restaurant demand in general. - MCD is seen as a value leader among QSR, so trade-down from casual dining could help.

Risks - U.S. comp deceleration is the clearest company-specific concern. The headlines raise the question of whether menu innovation can offset it. - "Higher for longer" rates (97% no-cut) cap multiple expansion for dividend and defensive stocks. - High gas prices and a possible inflation re-acceleration squeeze the lower-income consumer, which hits traffic. - Value-perception erosion, as in the "drive-thru splurge" piece, could weaken traffic even if average check rises. - ETF net selling (Oct. 19) is a minor negative flow signal.

What to watch - The exact U.S. comp figure and guidance from the latest earnings release, which I couldn't see. - The dividend declaration and ex-dividend date. - Real data for CPI, 10-year yield, and the Fed's stance, once the FRED feed is restored. - Peer read-throughs from Chipotle and Starbucks earnings and commentary on low-income traffic. - Gas prices and oil direction.

Summary table¶

Category	Key point	Evidence / source	Confidence	Trading relevance
Company: sales	U.S. comp growth slowing; menu innovation is the offset	Zacks and Simply Wall St. headlines	Medium (headline-only, no figures)	Main company-specific downside risk
Company: pricing/value	Drive-thru checks rising; value-perception risk	TheStreet headline	Low–Medium	Watch traffic versus check
Company: dividend	Possible Dividend King milestone; payout tied to ~Dec. 1	Motley Fool headline	Medium (confirm dates)	Income-buyer support, possible near-term catalyst
Company: flows	ETFs net sellers on Oct. 19	GuruFocus	Medium	Minor negative short-term flow
Company: governance	MCD objects to tokenized versions of its stock	WSJ, Unchained	High	Not financially material
Company: Israel franchise	Considering tech-led transfer	Simply Wall St.	Low	Small strategic item
Peers	Chipotle, Starbucks, and Pepsi under scrutiny for demand and margins	Trefis, Zacks, 24/7 Wall St.	Medium	Sector read-through is mildly cautious
Macro: Fed	97% chance of no cuts in 2026	Polymarket (~$9M volume)	High (market-implied)	Rate relief unlikely, caps defensive multiples
Macro: recession	8% chance of US recession by end of 2026	Polymarket (~$2.3M volume)	Medium–High	Soft-landing base case
Macro: inflation	16% for above 4.5%, 8% for above 5%; "inflation is back" headlines	Polymarket, Trefis	Low–Medium	Consumer squeeze, cost pressure
Macro: energy	Headlines cite $4.33 gas; oil slipping per WSJ	Trefis, WSJ	Low (no data)	Headwind for lower-income traffic
Macro: official data	CPI, rates, yields, labor, VIX unavailable	FRED tool errors	n/a	Gap: needs a rerun or another source

Bottom line for the next analyst: The news picture for MCD is cautious but not alarming: slowing U.S. comps, a stretched low-income consumer, and no Fed relief, offset by a defensive profile, dividend appeal, and a low recession probability. The biggest gaps are the actual comp and guidance numbers and any hard macro data (rates, inflation, yields). Fill those in before sizing a position.

Fundamentals Analyst¶

MCD (McDonald's Corporation) Fundamental Report¶

As of 2026-10-21 | Consumer Cyclical / Restaurants | NYSE

1. Summary¶

Fundamentals are improving while the stock has de-rated. In the first half of 2026, revenue grew about 6.4%, operating income about 7.0% and diluted EPS about 6.3% year over year. Operating margin held near 46–47%.
The implied price is about $245. That is P/E 19.92 × EPS $12.31, and it matches forward P/E 17.84 × forward EPS $13.75. It sits about 28% below the 52-week high of $341.75, about 14% below the 200-day average ($285.35) and about 2% below the 50-day average ($251.28). It is only about 7% above the 52-week low of $229.20.
Insiders have sold heavily and not bought. I count about $40.5M of open-market sales over roughly the past 11 months and no open-market purchases anywhere in the dataset. Nothing was filed in the past week.
My tools do not explain the price decline. They have no news, guidance or same-store-sales data. The next assistant should check those.
The Q3 2026 quarter (ended Sep 30) is not in my data. The latest reported period is the quarter ended 2026-06-30.

2. Company Profile and Valuation Snapshot¶

Metric	Value	Comment
Market cap	$173.56B	Large-cap
P/E (TTM)	19.92	Compressed from roughly 28x in Feb 2026 (see below)
Forward P/E	17.84	Implies about 11.7% EPS growth (13.75 vs 12.31)
PEG	2.57	Implies about 7.8% growth, so not cheap on a growth-adjusted basis
EPS (TTM) / Forward	$12.31 / $13.75
Dividend yield	3.13%	At about $245 this is roughly $7.67 per share a year, about 62% of TTM EPS (my derivation)
Beta	0.447	Low market sensitivity
Price-to-book / book value	-169.6 / -$1.45	Negative equity, so the ratio is not meaningful
FCF (TTM)	$6.26B	FCF yield about 3.6% of market cap
Revenue (TTM)	$27.70B
Gross profit	$15.90B	About 57% margin
EBITDA	$14.93B	About 54% margin
Net income (TTM)	$8.79B	31.7% net margin
Operating margin	46.5%
Return on assets	13.25%
Current ratio	1.081	Matches the balance sheet (4,345 / 4,018)

De-rating: TTM EPS is $12.31, and the quarterly EPS figures imply FY2025 EPS of about $11.95. Insiders sold at about $333 in Feb 2026, so the multiple then was roughly 28x. The multiple has since fallen about 29% while EPS rose. This is my inference from the tool data, not a stated fact.

3. Income Statement (quarterly, USD millions)¶

Q4 columns do not appear in the tool output, so only Q1–Q3 per year are shown.

Quarter	Revenue	Op. income	Op. margin	Net income	Diluted EPS
Q1 2025 (Mar)	5,956	2,648	44.5%	1,868	2.60
Q2 2025 (Jun)	6,843	3,232	47.2%	2,253	3.14
Q3 2025 (Sep)	7,078	3,357	47.4%	2,278	3.18
Q1 2026 (Mar)	6,517	2,953	45.3%	1,983	2.78
Q2 2026 (Jun)	7,099	3,338	47.0%	2,362	3.32

Year-over-year growth

Period	Revenue	Op. income	Net income	EPS
Q1 2026	+9.4%	+11.5%	+6.2%	+6.9%
Q2 2026	+3.7%	+3.3%	+4.8%	+5.7%
H1 2026 vs H1 2025	+6.4%	+7.0%	+5.4%	+6.3%

Q2 revenue growth slowed to +3.7% from +9.4% in Q1. The Q1 figure was flattered by an easy comparison, since Q1 2025 was the weakest quarter shown.
Q2 EPS growth of 5.7% is below the roughly 11.7% growth implied by forward EPS. The back half of the year needs to accelerate to reach that number.
Implied Q4 2025 (TTM minus the reported quarters) is revenue of about $7.0B, net income of about $2.16B and EPS of about $3.03. These are derived, not reported in the tool output.
Long-run trend (Q2 2008 to Q2 2026):
Revenue rose about 17%, from 6,075 to 7,099, after dipping to about 5.0B in 2019, consistent with a shift toward franchising.
Operating income rose about 100%, from 1,654 to 3,338.
Operating margin rose from about 27% to about 47%.
Diluted EPS rose about 219%, from 1.04 to 3.32.
Data caveat: The "Cost of Revenue" line (about $680M a quarter) is only a partial tag. It is about 10% of revenue and cannot be reconciled with the $15.9B TTM gross profit. I did not use it.

4. Balance Sheet (USD millions)¶

Date	Total assets	Current assets	Cash	Current liabilities	Equity
2024-09-30	56,329*	n/a	1,221	n/a	-5,177
2025-06-30	59,555	5,601	1,876	4,361	-2,760
2025-09-30	60,608	6,079	2,413	4,146	-2,163
2025-12-31	59,515	4,163	774	4,018**	-1,791
2026-03-31	60,037	4,709	1,170	4,146**	-1,286
2026-06-30	59,920	4,345	822	4,018	-1,023

*Total assets of 56,329 is the 2025-03-31 value. The 2024-09-30 column is shown only for the equity figure. **The current-liabilities cells for 2025-12-31 and 2026-03-31 are approximate and not reliable. I could not align the columns cleanly for those two dates. The Jun-2026 and Jun-2025 figures are reliable.

Negative equity is shrinking quickly. The deficit narrowed from -$5.18B (Sep 2024) to -$1.02B (Jun 2026). It improved by $263M to $505M a quarter over the last three quarters. If that pace holds, equity could turn positive in a few quarters. That is my extrapolation, not a forecast.
Liquidity is thin. Cash is only $822M and the current ratio is 1.08. This is normal for a franchisor with strong, predictable cash flow, but it leaves no cushion.
Total liabilities and debt are not available from my tools. Implied total liabilities are about $60.9B (assets minus equity). I cannot compute net debt, leverage or interest coverage.

5. Cash Flow (quarterly, USD millions)¶

Capex is shown as a positive outflow in the source data.

Quarter	Operating CF	Capex	FCF (OCF − capex)	Investing CF	Financing CF
Q1 2025	2,428	551	1,877	-771	-1,543
Q2 2025	1,998	744	1,254	-869	-555
Q3 2025	3,428	1,011	2,417	-1,112	-1,786
Q1 2026	2,412	682	1,730	-777	-1,225
Q2 2026	2,807	831	1,976	-868	-2,387

H1 2026 versus H1 2025:
Operating cash flow was $5,219M versus $4,426M (+17.9%).
Capex was $1,513M versus $1,295M (+16.8%).
FCF was $3,706M versus $3,131M (+18.4%).
Cash generation is growing faster than earnings, and capex is rising in step with it.
Dividend coverage is adequate but tight. TTM FCF of $6.26B against an implied dividend bill of about $5.4B (3.13% yield × market cap) gives roughly 1.15x coverage. That leaves limited room for buybacks without drawing on cash or debt. The dividend figure is my approximation.
Q2 financing outflow rose to $2.39B, about double Q1's $1.23B. The tool does not break out dividends, buybacks and debt repayment.
TTM FCF does not reconcile with the quarterly rows. The Q4 2025 cash flow is missing, and the three reported quarters sum to about $6.1B of FCF. That would imply a very small Q4. I used the vendor's $6.26B TTM figure and treat the quarterly rows as indicative only.

6. Insider Transactions (Oct 2024 – Aug 2026)¶

Last week: No transactions. Most recent entry: 2026-08-07, Lauren Elting, 1,038 shares disposed. No price is listed, so it is likely a non-market disposal such as tax withholding on vesting. The tool does not say. Most recent priced sale: 2026-06-10, Joseph Erlinger, 5,252 shares at $284.32 ($1.49M).

Open-market sales from 2025-11-05 to 2026-06-10 (20 transactions) - About 127,000 shares for about $40.5M. - Zero open-market buys in the entire dataset.

Insider	Role	Date	Shares	Price	Value
Kempczinski, Christopher	CEO	2026-02-13	52,553	~$331–334	$17.47M
Borden, Ian	CFO	2025-11-21	17,134	$310.00	$5.31M
Steijaert, Manuel	Officer	2025-11-05 / 12-01	13,134 / 6,567	~$300 / $305.50	$3.95M / $2.01M
Banner, Jonathan	Officer	2026-02-23	6,200	~$333	$2.07M
Flatley, Edith	Officer	2026-02-12	4,692	$331.00	$1.55M
Erlinger, Joseph	Officer (President in a 2025 entry)	Monthly, Nov 2025 – Jun 2026	~2,626 each (333 on some)	$280–$328	~$0.1–1.5M each
Ralls-Morrison, Desiree	Officer	2025-12-16 / 2026-05-28	2,486 / 2,763	$320.00 / $278.36	$0.80M / $0.77M

Many sales followed option exercises. The CEO exercised 73,281 options at $128.09 and sold 52,553 shares. The CFO exercised options at $116.73 and sold 17,134 shares. This is consistent with monetizing in-the-money options, not necessarily a bearish view.
Erlinger's sales look scheduled. He sold 2,626 shares (after exercising options at $157.79) on roughly the 10^th of each month, plus 333 shares around the 23^rd. That pattern looks like a pre-arranged plan, though the tool does not confirm it.
Sales slowed as the price fell. Priced sales ran from about $333 in Feb 2026 to about $278–$284 in May–June 2026. There have been none since June, so no insider has sold near the current price of about $245.
No insider bought at the lower prices. I see no insider buying at roughly $245–$285, which is a lack of confirming signal, not a bearish signal.
Several February 2026 entries show shares but no price or value. These include the CFO, Baroni, Banner and others on 2026-02-13. I did not count them as market sales.
Gifts were made. The CEO gifted 31,842 shares in May 2025 and the CTO gifted 8,789 shares in Oct 2025. These are not economically meaningful for trading.

7. Key Takeaways for Traders¶

Supportive 1. EPS is compounding at about 6% on a margin structure near 47% operating and 32% net. 2. Free cash flow is growing at about 18% in H1 2026, and the dividend yield is a high 3.13% for a stock with a beta near 0.45. 3. The multiple has compressed to about 17.8x forward earnings, which is below where insiders were selling a few months ago. 4. The equity deficit is narrowing steadily.

Cautionary 1. Q2 revenue growth slowed to +3.7% from +9.4%, and Q2 EPS growth of 5.7% trails the roughly 11.7% implied by forward EPS. 2. The PEG of 2.57 shows the stock is not cheap versus its growth. 3. Dividend coverage by FCF is about 1.15x, and cash is thin at $822M. 4. Rising capex (+17% in H1) absorbs part of the cash flow improvement. 5. Insiders sold about $40M and have not bought. 6. The price is below both its 50-day and 200-day averages, and I do not know why. 7. I cannot assess leverage or interest burden because the debt data is missing.

What to watch - Q3 2026 earnings (quarter ended Sep 30): Not yet in my data and not yet reported. - Revenue growth should be at least in the mid-single digits. - Operating margin should hold around 47%. - Watch whether EPS growth moves toward the roughly 11.7% implied by forward EPS. - Watch whether capex and the financing outflow stay elevated. - Insider filings: Watch for the first open-market purchase, or for sales resuming at lower prices. - Price levels: The $229.20 52-week low and the $251 and $285 moving averages are the reference points.

8. Data Gaps¶

No debt, interest expense, share count, buyback or dividend-per-share lines.
Gross profit and total liabilities are marked "unavailable".
The Q4 columns are missing from the income statement and cash flow, and the Q3 2026 quarter is not yet reported.
No same-store sales, segment data, guidance, news or analyst estimates were available.

9. Summary Table¶

Category	Key point	Evidence	Read-through
Valuation	P/E 19.9, forward 17.8, PEG 2.57	Implied price about $245	Moderate valuation, not cheap on growth
Price context	28% below 52-week high, 14% below 200-day average	$341.75 / $285.35 / $251.28	Downtrend; cause not covered by my tools
Growth	H1 2026 revenue +6.4%, EPS +6.3%	Q2 revenue +3.7%, EPS +5.7%	Steady but decelerating in Q2
Profitability	Op. margin 46.5%, net margin 31.7%	Q2 2026 op. margin 47.0%	Elite and stable
Cash flow	H1 FCF +18.4%; TTM FCF $6.26B	Capex +16.8%	Strong; FCF yield about 3.6%
Dividend	Yield 3.13%, FCF coverage about 1.15x	Derived from yield × market cap	Adequate but tight; limits buyback room
Balance sheet	Equity -$1.02B, improving; cash $822M; current ratio 1.08	Deficit was -$5.18B in Sep 2024	Liquidity thin; debt not visible
Insiders	About $40.5M sold, 0 buys	CEO $17.5M at about $332; none since June	Mostly option-exercise or scheduled selling; no buying support
Risk profile	Beta 0.447		Defensive profile
Data gaps	No debt, buyback, comps or Q3 data		Leverage and Q3 need other sources

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for MCD at $245.28: A De-Rating, Not a Deterioration

I'll open with what I think is the central fact in this debate. MCD's stock fell about 27% from its February closing high of $334.50, but its earnings did not fall. H1 2026 revenue grew 6.4%, operating income 7.0%, and diluted EPS 6.3%. The stock lost value because the multiple compressed, from roughly 28x in February to 19.9x trailing and 17.8x forward. A 29% multiple haircut on a business that is still compounding is a different problem from a broken business.

1. The business is as good as it ever was¶

Margins: Operating margin is 46.5% and net margin 31.7%. Operating margin was about 27% in 2008. Since then, diluted EPS is up roughly 219% on revenue up only 17%. That is what a franchise model gets you.
Cash flow: H1 operating cash flow rose 17.9% and free cash flow rose 18.4%. Trailing FCF is $6.26B, a 3.6% yield.
Balance sheet trajectory: The equity deficit has shrunk from -$5.18B (Sep 2024) to -$1.02B (Jun 2026). That is $263M to $505M of improvement a quarter.
Dividend: The yield is 3.13%, roughly $7.67 a share, and the stock has a 0.447 beta. The Dividend King milestone and the Dec. 1 holding-date hook give income buyers a reason to show up.

2. Higher for longer is already in the price¶

Polymarket puts the chance of no Fed cuts in 2026 at 97%. That is the most liquid macro market we have, and it is no secret. The multiple has already fallen about 29% while EPS rose. The bear needs rates to get worse than consensus for this to hurt further. Meanwhile, recession odds are only 8%, which supports a consumer-facing defensive.

3. The technical picture shows a washed-out stock that is repairing¶

Capitulation: Sept. 23 was a -4.8% day on 16.6M shares, the heaviest volume in the dataset. RSI then spent 11 straight sessions below 30 and bottomed at 21.78.
Reversal: On Oct. 8 the stock rose 2.6% on 11.4M shares, the start of a high-volume reversal.
Volume flow: OBV has recovered faster than price. It is back above its Sept. 22 level while price has recovered only about 74% of that drop.
Trend: The daily SuperTrend is up, price is above the 10 EMA, and RSI has held above 50 since Oct. 15.
Longer-term exhaustion signals: The monthly z-score is -1.78 and the monthly TD count is 7 of 9.

4. Insider selling is weaker evidence than it looks¶

About $40.5M was sold, but look at the details:

The sales were mostly option exercises (CEO exercised at $128, CFO at $117) and what looks like a scheduled monthly plan (Erlinger, around the 10^th of each month).
They happened at $280 to $333, when the stock traded near 28x earnings.
No one has sold since June, and nobody has sold anywhere near $245.

Insiders monetizing in-the-money options at 28x says nothing about whether the stock is fairly valued at 17.8x forward.

5. Risk/reward is defined¶

I'm not claiming the weekly and monthly trends have turned. They haven't, and I'll concede that now. But a bull case doesn't need to call a bottom. It needs an asymmetric setup:

Risk: The daily SuperTrend stop is $232.28, and the 3x ATR stop is about $232.35. That is about 5% below the current price. The closing low is $230.88 and the 52-week low is $229.20.
Reward: The weekly SuperTrend flip level of $265.86 is +8.4%. The 200 SMA at $282 is +15%. The reported Citi target of $295 is +20%, though that is retail hearsay I can't verify.
Ratio: That is roughly 1.6:1 to the first target and 2.8:1 to the second. If the stock takes the daily TD 9 pause and pulls back to the 10 EMA ($241) or the Bollinger midline ($236.70), a stop at the closing low gives about 5:1 to $265.86.
Carry: The stock pays a 3.1% dividend while you wait.

Where I expect the bear to push, and my answers¶

"Q2 revenue growth slowed to 3.7% from 9.4%." Q1 2025 was the weakest comparison quarter in the data, which flattered Q1 2026. H1 at +6.4% is the cleaner lens, and Q2 operating margin held at 47.0%.

"Forward EPS needs 11.7% growth, but you're seeing 6%." Fair, and the back half has to accelerate. But I don't need the forward number. At 6% growth, next year's EPS is about $13.05, which puts the stock at about 18.8x for one of the highest-quality franchise models in the market.

"U.S. comps are soft and the consumer is stretched." This is the real debate, and I'll grant it's the best bear point. But headlines like "drive-thru is becoming a splurge" and the $4.33 gas stories hint at trade-down pressure on other restaurants. MCD is the value anchor for that shift. Q3 earnings, not yet reported, will settle this.

"Dividend coverage is only about 1.15x FCF." My approximation puts the dividend at about 62% of EPS, and FCF is growing at 18%. Capex is rising in step (+16.8%), and that is discretionary growth spending, not maintenance.

Where I'm uncertain¶

I don't have the Q3 results, same-store sales figures, guidance, debt levels, or an explanation for the September breakdown. The Oct. 21 bar may also be a partial print. I'd rather say that now than have the bear find it. If Q3 shows comps deteriorating and margins cracking, I'll revisit.

Bottom line: A 47%-margin franchisor with growing earnings, 18% FCF growth, a 3.1% yield and a shrinking equity deficit now trades at about 18x forward earnings, after a volume-confirmed capitulation and reversal. The stock is cheaper by a third on multiple, while the business keeps compounding.

Bear, over to you. What breaks the earnings power from here? Bull Analyst: # Bull Rebuttal on MCD at $245.28: I'll Give Ground Where It's Owed, and Hold It Where It Isn't

You landed several real hits, so I'll start with what I'm giving up.

What I concede¶

Q3 status. I said Q3 was "not yet reported." The tools only show it isn't in the dataset, so I can't support that claim. I'll address it directly below.
FCF growth. The +18% is mostly a Q2 base effect. Q1 FCF fell 7.8% and Q2 rose 58% off a weak $1,254M comp. I shouldn't have sold it as acceleration.
Trade-down. "MCD is the value anchor" is a hypothesis, not evidence. The "$5 large fry" complaint is about MCD.
"Priced in." I can't verify it without a 10-year yield, and "97% no cuts" says little about 2027.
Monthly TD 7 of 9. It's an unfinished countdown, not a signal.
Citi's $295 target. It's hearsay, so I'm dropping it.
Entry price. At $245.28, risk/reward is thin. With a stop at $232.28, it's 1.6:1 to $265.86. With the stop at the $229.20 intraday low, it's 1.3:1. That's not a level to chase.

1. "Most of the loss came after June 30" isn't supported¶

The June 10 Erlinger sale was at $284.32. From the $334.50 high to $284.32 is -15%, about $50 of the $104 closing decline (roughly half). That happened while Q1 operating income was growing 11.5% and Q2 was still ahead.

That half was a de-rating without deterioration. The second half, from about $284 to $231, is where your "something newer" argument has force, and the burden of proof is on me there. But the evidence for impairment in that leg is headlines about softer U.S. comps with no figure attached. You're inferring from titles, and so am I.

2. Cash flow: the right lens is H1, not one quarter¶

You used quarterly splits when they helped and H1 when they didn't. Cash flow has timing noise (Q2 2025 OCF was $2.0B, Q3 was $3.4B), so H1 is the fairer view:

H1 financing outflow was $3.61B against H1 FCF of $3.71B. The company returned roughly all its free cash flow.
Cash went from $774M to $822M. Q2's $2.39B outflow looks alarming in isolation, but over H1 the business funded everything internally.
H1 OCF of $5.2B against a half-year dividend of roughly $2.7B (my approximation) is about 1.9x.
Capex is up 16.8% against H1 revenue up 6.4%, not the Q2 figure of 3.7%. Capex went from about 10.1% to 11.1% of revenue. That's a real watch item, but OCF as a share of revenue rose from about 34.6% to 38.3%.

Your two balance-sheet points may also be one fact. If Q2 capital return stepped up, financing outflows would jump and the equity-deficit improvement would shrink, which is what both numbers show. That's inference, since the tool doesn't split buybacks from debt paydown. But I wouldn't call it two separate warnings.

3. Valuation: your $222 needs a 15% further de-rating¶

Your $222 is 17x on $13.05. That EPS is what MCD earns over the next 12 months, so at that horizon it's a trailing multiple, down from 19.9x today. It requires another ~15% compression after the 29% already taken.

12-month scenario ($13.05 EPS, ~$7.7 dividend)	Price	Total return
Trailing P/E compresses to 17x	$222	about -6%
Trailing P/E holds at 19.9x	$260	about +9%
Trailing P/E recovers to ~22x	$287	about +20%

PEG above 3 ignores the yield. This isn't a screaming bargain. It's a roughly 9% expected return at a constant multiple, from a 3.1% yield plus about 6% growth, with a beta of 0.45. I'll also take your forward-EPS point: $13.75 needs a 23% H2 jump if it's a 2026 figure, so I'm anchoring on $13.05.

4. Your rotation story is my story¶

You say the stock fell because money is rotating out of defensives into AI and mega-cap tech. That's a multiple explanation, not an earnings one, and rotations do reverse. For the bear case to hold, earnings power must be impaired. The real candidate is U.S. comps, which I agree is the central risk. Q2 consolidated revenue of +3.7% with a 47.0% margin says the royalty stream is still growing, but it can't tell us the U.S. comp.

5. Technicals: a double bottom to the penny¶

The closes of $230.94 (9/30) and $230.88 (10/7) are six cents apart. That's a retest, not "lower lows." RSI troughed at 21.78 on 9/30, so the second test came with higher RSI, a mild positive divergence.
OBV is above its pre-break level, but I accept it's mild and Oct. 8 carries a lot of it.
The daily TD 9 and +1.77 z-score both rest on a bar the report says may be partial (2.6M shares against a 4–6M norm). I'm not building a thesis on them in either direction.
Your overhead supply list is right: $246.41, $250.18, $257.49, then $265.86. The path isn't clear.

6. Insiders: a constant isn't a signal¶

There are zero open-market buys across the entire 22-month dataset, including at $290–$330. Absence at $245 is the same as absence everywhere, so it can't distinguish anything. The CEO's February sale followed a $128 option exercise, and H1 shows no operating damage from whatever he supposedly saw. I'll grant it's a missing confirmation.

Your question: what's the catalyst, and why before the next leg down?¶

I don't need to win the sequencing race, because the entry plan doesn't depend on it.

Q3. Either it has been reported and the soft-comp news is known, with the stock up 6% off the low, or it's pending. I can't tell which, and the IR calendar should be checked first. If it's pending, I'd hold size small until it prints.
Entry. You said a pullback toward $237 is a better entry. So do I. The plan is bids at $241 and $236.70 with a stop below $229.20.

Entry	Stop	Reward to $265.86	Ratio
$236.70	$229.20	$29.16 vs $7.50 risk	~3.9:1
$241.24	$229.20	$24.62 vs $12.04 risk	~2.0:1

If it never pulls back, your alternative is a weekly close above $265.86, which means paying about 8% more for the same business.
Smaller supports: reclaiming $250 and filling the 9/23 gap, the Dec. 1 dividend-date flow (income demand, not a re-rating), and the rotation reversing, which is on your own list of what would make you wrong.

What would prove me wrong¶

A daily close below $229.20
Q3 with negative U.S. comps or operating margin below 46%
A guidance cut
A failed retest at $250 followed by new lows

Bottom line¶

We now agree on the entry. The remaining gap is whether MCD's multiple falls another 15%, to 17x trailing, or the 47%-margin franchise gets a 9%-total-return price. I'd bid for the second at $237–$241 and let the stop manage the first. Bull Analyst: # Bull Final on MCD at $245.28: The Argument Is Down to One Question

We now agree that $245 isn't a chase and that U.S. comps are the swing factor. Here is what I'm giving up and what I'm keeping.

What I'm giving up¶

Dividend coverage. You're right that I used OCF, which is before capex. On FCF it's 1.37x for H1 and 1.15x TTM. Thin, not alarming, but not the 1.9x I quoted.
Q1 sell-through. If the stock fell from ~$295 to ~$271 around a +11.5% operating income print, that print alone doesn't prove mispricing. I'm dropping it as proof.
Rotation reversal. I can't name a trigger from this data, so it's no longer a pillar of my thesis.
EPS base. If Q2 is the run-rate, operating growth is 3.3% and $12.72 belongs in my downside case.
Ratios aren't edge. A 3.9:1 setup has about a 20% hit rate on a driftless walk (7.50 / 36.66), which is zero expectancy. The edge has to come from drift, meaning the yield, EPS growth and a multiple that has already compressed. The ladder only sizes the risk.

1. The below-the-line story reverses over H1¶

You said EPS growth "leans on" non-operating items, using Q2's +1.5 points. Here are all three periods:

Growth YoY	Op. income	Net income	EPS	NI minus op. income	EPS minus op. income
Q1 2026	+11.5%	+6.2%	+6.9%	-5.3 pts	-4.6 pts
Q2 2026	+3.3%	+4.8%	+5.7%	+1.5 pts	+2.4 pts
H1 2026	+7.0%	+5.4%	+6.3%	-1.6 pts	-0.7 pts

Q2's tailwind is partly a reversal of Q1's headwind. Over H1, EPS grew slower than operating income, even with the ~0.9 points of share-count help you derived. I can't tell from the tools what drove Q1's gap (interest, tax or one-offs), so I wouldn't read either quarter as a signal. But EPS growth has been 5.7% to 6.9% in both quarters, which supports $13.05 as a base and $12.72 as a downside, not the reverse.

2. Your own table gives the break-even¶

Using your sensitivity rows (total return including yield):

3.3% growth at 19.9x: about +6%
3.3% growth at 17x: about -9%

The 12-month expected return stays positive unless the 17x row is more than about 40% likely, before counting any re-rating upside. That scenario needs another ~15% compression after the 29% already taken. I have no multiple history in these tools, so neither of us can claim a floor. That makes it a probability judgment, and I don't see evidence in the data that it's more likely than not.

3. Gap risk is a cost, not a veto¶

Your gap math is directionally right. A Sept. 23-sized move (-4.8%) from $236.70 lands near $225.3:

Bid	Stop	Target	Clean ratio	After a -4.8% gap	Break-even hit rate
$236.70	$229.20	$265.86	3.9:1	loss ~$11.4, ~2.5:1	~29%
$241.24	$229.20	$265.86	2.0:1	lands at $229.66, above the stop	~33%

The gap-through risk applies only to the lower rung. Adverse selection is real for any limit bid, but it's already in the break-even column. The $265.86 target is a hurdle with four levels in front of it, so I'd expect partial exits along the way. I'm not claiming a clean run.

4. The print is the gate, so I'll size around it¶

From memory, not these tools, Q3 usually lands in the last days of October, so I'll grant a pending print is more likely than not. The IR calendar should be checked before anything else. I also concede that the cost of waiting isn't only "a few points". A good print could gap MCD into your $250–$257 supply zone, where the entry R/R is poor.

So I'm amending the plan:

Pre-print: a small starter, about a third of intended size, at $241 or below. The $236.70 rung is held back until after the print.
Post-print: if U.S. comps are flat or better and operating margin is ~47% or above, add on a hold above $229.20. This is your own buy condition.
Unchanged: a close below $229.20 ends the trade.

We now differ only on whether a one-third starter ahead of the print is acceptable. I call it sized risk, and you call it a sequencing bet. After the print, our plans are the same.

5. Why I still lean long¶

The multiple already reflects the doubts. The stock is 17.8x forward, down 29% in multiple while H1 EPS grew 6.3%. It has also absorbed this week's soft-comp headlines and still rose ~6% off the low. That's modest evidence expectations are low, not proof.
Drift is positive. The case is a 3.1% yield plus ~6% EPS growth, about 9% at a constant multiple, from a 47%-margin franchisor with a 0.45 beta.
The risk is defined. The stop sits ~3% below the $236.70 rung and ~5% below the current price.

What would prove me wrong¶

A close below $229.20
Q3 with negative U.S. comps and operating margin below ~46%
A guidance cut
A failed retest of $250 followed by new lows

My question back¶

You'd buy a post-print pullback to $237–$241, the same zone as my bids. So name the Q3 U.S. comp number and operating margin that make you buy, and the ones that make you sell. If the buy zone is the same price either way, "wait for the print" has to rest on thresholds, or it's just avoiding a decision.

Bottom line: MCD is a constructive hold-the-line story with a scaled entry. It isn't a buy at $245, and it isn't a short at 17.8x forward with a growing 47%-margin franchise. I'd start small below $241 and add only after Q3 confirms comps. Bull Analyst: # Bull Close on MCD at $245.28: The Dispute Is Smaller Than the Debate

We agree that $245.28 isn't a buy, that MCD isn't a short at ~19x for a 47%-margin franchise, and that U.S. comps and margin decide it. Thanks for putting numbers on the thresholds. Here is what I'm giving up, then the one place I still disagree.

What I'm giving up¶

17.8x forward. It rests on $13.75, which needs about +23% in H2 if it's a 2026 figure. On $13.05 the stock is 18.8x, and on your $12.63 it's 19.4x.
The 40% break-even. A zero hurdle was wrong.
The ladder as an edge. On your numbers (a 36–38% hit rate against a 33% break-even), the edge is about $1.15–1.90 a share against $12 at risk. A one-third starter is worth about $0.40–0.60 per full-position share. I won't claim more.
Stop mechanics. A close-based stop doesn't cap a gap, so size on the gap case.
My ~46% margin line. It was too loose. At 47.0% on +4% revenue, operating income grows about 3.1%, which is the $12.72 case.
Q3 is a hard comparison. Q3 2025 had the highest margin in the table (47.4%). I won't argue Q4 is easier, because I have no Q4 2024 data and Q4 margins may just be seasonal.

1. EPS base: a range, with $12.63 as the floor¶

I'll take $12.63 as a defensible downside, so NTM EPS is $12.63–$13.05 (+2.6% to +6.0%). At a constant 19.9x, that is $251.6–$260. Adding the 3.1% yield gives about 6–9%.

Against your 4% cash placeholder (unverified, since FRED failed), the excess return is about 2–5 points before any change in the multiple. That is thin, and it's why my position is a starter and not a conviction long. Both tails exist: 22x gives about $278–$287, and 17x gives about $215–$222. With no multiple history, neither of us can weight them with confidence.

2. Size on the gap, and the starter is optional¶

From $241.24, a Sept. 23-sized gap lands at $229.66. Your −8% case lands near $222, a $19 loss. I'd size the starter so that outcome is tolerable. At a third of full size, it costs about 2.7% of full-position value.

I'd rather not fight over $0.50 a share of expected value. If the IR calendar shows Q3 within days, I'll skip the starter, because a binary event dwarfs sub-$1 of drift. If it's weeks away, a small starter at $241 or below is fine.

3. Where I still disagree: your table asks for improvement, not intactness¶

Suppose Q3 simply repeats Q2's year-over-year rates:

	Q3 2025	Q3 2026 if Q2's YoY rates repeat	Your bucket
Revenue	$7,078M	~$7.34B (+3.7%)	Stay out (≤ +4%)
Operating margin	47.4%	~47.2% (−0.2 pt)	Mixed (47.0–47.4%)
Diluted EPS	$3.18	~$3.36 (+5.7%)	Mixed (just under $3.37)

That "nothing changes" print is the one that supports roughly $13.0 of NTM EPS, my base. Your table classes it as stay out or mixed, so it demands re-acceleration. That's a stricter test than "is the thesis broken." A re-accelerating print is also the one that gaps the stock into $250–$257, where neither of us wants to buy. In practice, nearly every outcome becomes "wait for a pullback." That's coherent, and you've accepted the cost.

But your own rule says a mixed print is followed by "a post-print hold above $229.20." That is close to my add trigger, so the real gap is the definition of "hold" and the size. My proposal:

Starter (up to ⅓): at $241 or below, and only if the print isn't imminent.
Add to about ⅔: after a print with U.S. comps flat or better, operating margin of at least 47.0%, intact guidance, and five sessions with no close below $229.20.
Full size: only on your buy-eligible column (revenue ≥ +5%, margin ≥ 47.4%, EPS ≥ $3.37).

Where we land¶

	Agreed	Open
$245.28 is not a buy; not a short	✔
U.S. comps and margin decide it	✔
Post-print buy zone of $237–$241	✔
Pre-print starter		Optional, worth under $1 a share either way
Post-print trigger		"No break plus a hold" vs. "improvement"
Sizing		I size on gap loss; you'd wait

Bottom line¶

MCD is a high-quality, low-beta franchisor with a 6–9% constant-multiple return and no verified floor on the multiple. That is a measured, staged accumulation, not a table-pounding long. I'm no longer defending "cheap at 17.8x."

I'm wrong, and out, on any of these: - A close below $229.20 - Negative U.S. comps - Operating margin below 47.0% - Diluted EPS at or below $3.28 - A guidance cut

The facts neither of us has are the Q3 date, the U.S. comp, and the debt load, and the plan above is built around them. Bull Analyst: # Bull Close on MCD at $245.28: The Gap Is a $4 Ceiling

We agree that $245.28 isn't a chase, that MCD isn't a short at about 19x for a 47%-margin franchise, and that Q3 U.S. comps and margin decide it. Below are my concessions and the one point I'll still defend.

What I'm giving up¶

$12.63 isn't a floor. My "Q2 rates repeat" row carried Q2's +2.4-point EPS-over-operating gap forward. Applying H1's gap instead gives about $3.26 (3.18 × 1.026) and $12.63 NTM. H1's gap averages two offsetting quarters (−4.6 and +2.4), so neither it nor Q2's gap is a clean run-rate. A status-quo Q3 is therefore $3.26–$3.36, or $12.63–$13.05 NTM, and the real downside sits below that range.
Your relabeled buckets. No-add and exit are different, and I'll use your table.
The pre-print starter. I'm dropping it. Its expected value was under $1 a share, and a binary print outweighs that. From memory, not these tools, MCD's Q3 reports have landed anywhere from about Oct. 28 to Nov. 6 in recent years. I can't confirm the date, but the print is close. Pre-print I set alerts and place no orders.
Re-rating tails. I've retired 17.8x, "priced in," the rotation reversal and the Citi target. Nothing in my plan needs a re-rating.

What I'm still defending: the price limit on a mixed-print add¶

You're right that, before the print, $245 pays only 1.7 to 5.1 points over a 4% cash placeholder (unverified, since FRED failed) for a binary event. After the print, two things change.

That premium is compensation for the event. After a mixed print and five sessions holding above $229.20, the event has resolved. The same points then pay for a position with its main unknown gone.
A price limit belongs in the rule. "Add wherever the hold happens" was too loose. Using your grid (19.92x, $7.67 dividend):

Entry	Total return at $12.63	Total return at $13.05	Low case vs. 4% placeholder
$236.70	+9.5%	+13.0%	+5.5 pts
$241	+7.6%	+11.0%	+3.6 pts
$245	+5.7%	+9.1%	+1.7 pts
$250	+3.7%	+7.0%	−0.3 pts

The low case stops clearing the hurdle at about $250, so I'll set a hard ceiling of $245 for a mixed-print add. That's where status quo still pays about 2 points over cash. You'd set it at $241. The difference is 1.7% of price and about 2 points of low-case return, and the post-print tape will settle it better than either of us can now.

Why the plan is still worth having¶

No re-rating is needed. At a constant multiple, status-quo EPS and the dividend give 5.7–9.1% from here. That comes from a 0.45-beta business with 46–47% operating margins and $6.26B of TTM FCF.
The exits are written down. I exit on a close below $229.20, negative U.S. comps, operating margin below 47.0%, EPS at or below $3.28, or a guidance cut.
Leverage is a gap, not a finding. Neither of us can see debt or interest coverage, and the gap cuts both ways. Before sizing past a partial position, I'd pull both.
On a good print I agree with you. If the stock gaps into $250–$257, I wait for a hold or a weekly close above $265.86. Paying up there is a re-rating bet.

Where we land¶

	Status
$245.28 is not a buy and not a short	Agreed
Q3 U.S. comps and margin are decisive	Agreed
Your thresholds, with no-add and exit buckets	Agreed
Five sessions with no close below $229.20 as the minimum hold	Agreed
Don't chase a gap into $250–$257	Agreed
Pre-print starter	Dropped
Mixed-print add ceiling	Open: $245 (me) vs. $241 (you)

Bottom line¶

MCD at $245.28 is a watchlist name with a plan, not a buy. The data we have shows an intact franchise, and the constant-multiple return is positive. The plan commits capital only after the unknown resolves, with hard thresholds, a hold above $229.20 and a $245 ceiling. If the print is good and the stock gaps away, I pay the cost of waiting. If it's bad, I pay nothing.

Before anything else: - Check the IR calendar for the Q3 date, and whether it's already out. If it is, the thresholds table is a lookup against actuals. - Set alerts at $241, $236.70, $232.28 (daily SuperTrend flip), $229.20 and $265.86 (weekly flip). - Pull debt and interest coverage before sizing beyond a partial position.

Bear Researcher¶

Bear Analyst: # Bear Case for MCD at $245.28: You're Buying a Falling Knife on Stale Data

You open with "a de-rating, not a deterioration." I don't think that distinction holds. The multiple is the market's estimate of future earnings, and every number you cite stops on June 30. The stock lost most of its value after that.

1. Your evidence ends before the sell-off does¶

You say the business is "as good as it ever was," but you also admit you don't have Q3 results, comps, guidance, debt levels, or an explanation for September. The stock fell 4.8% on 16.6M shares, the heaviest volume in the dataset, and then ground to a lower low two weeks later. A stock doesn't lose 31% peak to trough on a business that is "as good as ever." Either the market knows something that isn't in H1 numbers, or it's wrong for reasons you can't name. The headlines about slower U.S. comps point to the first explanation.

You also say Q3 is "not yet reported." The tools only tell us it isn't in the dataset. The news report couldn't confirm whether a recent print has happened, and one StockTwits user refers to an earnings crash. Your thesis rests on a catalyst whose status you can't verify.

2. Applying your "easy comp" argument consistently¶

You dismissed the slowdown in Q2 revenue growth (+9.4% to +3.7%) by saying Q1 was flattered by an easy comparison. If so, H1's +6.4% is the inflated number, and Q2 is the better run-rate. You can't use that argument on revenue and ignore it elsewhere:

Operating income grew only 3.3% in Q2. Operating margin was 47.0%, down from 47.2% a year earlier. "Held" is generous.
EPS growth of 5.7% outran operating income by 2.4 points. The help came from below the line (interest, tax, share count), not from the business.
The 18% FCF growth is a base effect. Q1 2026 operating cash flow was $2,412M against $2,428M a year earlier, and Q1 FCF fell 7.8%. All the H1 growth came from Q2, which rose 58% against a weak $1,254M comparison. Q3 2025 FCF was $2,417M, so the next quarter faces a much harder comp.
Capex is up 17% while revenue is up 3.7%. You call it "discretionary growth spending," but the return isn't visible yet.

3. The valuation case depends on anchoring to the peak¶

You measure "cheap" against 28x, but 28x was the outlier. The question is what a 6% grower deserves. At your own conservative $13.05 EPS, 18.8x implies a PEG above 3. The vendor PEG is already 2.57.

On the forward number, the tool doesn't say whether $13.75 is a 2026 or a 2027 estimate:

If it's 2026, H2 EPS has to jump about 23% against about $6.21 in H2 2025, when H1 is running at +6%.
If it's 2027, the stock is 17.8x for roughly 6% growth.

Neither is a bargain. Your 219% EPS growth since 2008 came from operating margin rising from 27% to 47%, which was the refranchising story. That runway is used up. Revenue is up just 17% in 18 years, so future EPS growth has to come from the top line, which is decelerating.

You say the bear needs rates to get worse. I only need the multiple to stop being generous. At 17x on $13.05, MCD is $222, 9.5% lower and well through your $232 stop.

4. The macro and consumer arguments cut against you¶

"97% no cuts" is mostly a calendar fact. With about two FOMC meetings left in 2026, it says little about the 2027 rate path, which is what valuations discount. We also have no 10-year yield, because the FRED pull failed. "Priced in" isn't something either of us can verify.
Your two claims conflict. If the business is fine and rates are priced in, why did the stock fall 27%? A more coherent story is rotation out of defensives. Recession odds are only 8%, so there's no flight-to-safety premium, and the market's attention is on AI and mega-cap tech earnings. That rotation isn't finished.
MCD isn't the trade-down beneficiary in the data. "The drive-thru is becoming a splurge" is about fast food, and MCD is its face. The retail complaint about a "$5 large fry" is about MCD. The slower U.S. comps headlines are MCD-specific. Chipotle, Starbucks and Pepsi are all under scrutiny too. With $4.33 gas, "inflation is back" headlines, and a 16% market-implied chance of inflation above 4.5%, lower-income traffic is the vulnerable spot. Low recession odds don't fix a squeezed consumer.

5. The balance sheet and dividend aren't the comfort you describe¶

The equity-deficit improvement is slowing. The last three quarters were +$372M, +$505M, then +$263M. You quoted the range, but the low end is the latest quarter. Equity is also an accounting residual, and nobody here has seen the debt.
Q2 financing outflows ($2.39B) exceeded FCF ($1.98B). Cash fell from $1.17B to $822M, with a current ratio of 1.08.
Coverage is about 1.15x FCF. That leaves little room for buybacks without drawing on cash or debt.
The 3.13% yield is a function of price. It rose because the stock fell. The Dec. 1 catalyst is a quarterly payment of roughly $1.92, about 0.8% of the share price. The stock fell more than that on Sept. 23 alone.

6. The technicals support me more than you¶

You conceded the weekly and monthly trends are down. The tool says to weight higher tiers, and they are down, with the 50 SMA below a still-falling 200 SMA. The rest of your list doesn't hold up:

The "capitulation" didn't mark the low. The heavy-volume day closed at $238.32. The stock then made lower lows at $230.94 and $230.88. A real capitulation is usually the low.
The monthly TD 7 of 9 isn't a buy signal. It's an unfinished countdown that only completes if the downtrend persists for two more monthly bars. The -1.78 monthly z-score shows a downtrend in progress. You cite the extreme you like on the monthly and wave away the daily +1.77 z-score and the completed daily TD 9.
OBV is back to even, not ahead. It's -34.76M versus -37.11M before the break, on a baseline that was already deeply negative from months of distribution. The "divergence" is mild, and one big reversal day (Oct. 8) carries a lot of it.
Momentum is rolling over. RSI dropped from 58.18 to 55.61, and the MACD histogram has flattened with both lines below zero. In downtrends, RSI rallies tend to stall in the 55 to 65 zone.
Overhead supply is stacked. The stock faces the upper band at $246.41, the 50 SMA at $250.18, the Sept. 14 close at $257.49, and then $265.86.

On risk/reward, your ratio is about 1.6:1 to the first target, with $232.28 as the stop. The "$295 Citi target" is the retail hearsay you flagged yourself, and it also implies a target cut. Your 5:1 setup comes from buying at $236.70, which concedes that $245.28 isn't the entry. A stop at $230.88 would then sit only 1.35 ATR away, which noise could easily hit. I agree with your own best trade: wait.

7. Insiders¶

You're partly right. The option exercises and Erlinger's schedule make the $40.5M less damning. But $17.5M from the CEO six weeks before the first leg down is the only price signal management has given us. There have been zero open-market buys in the entire dataset, including at 17.8x forward. If management saw a de-rating on a compounding business, a purchase would have been the cheapest way to say so.

Where I could be wrong¶

Q3 shows comps recovering and EPS growth moving toward 10%.
A weekly close above $265.86 shows the higher-tier trend turning.
An insider buys at these prices.
The rotation out of defensives reverses.

None of that is in evidence today.

Bottom line¶

The H1 data is decent, but the market has been telling us since September that something more recent isn't. The growth is about 6% and decelerating, and the FCF "acceleration" is a base effect. Leverage is invisible, liquidity is thin, and the consumer story points against MCD. The technical bounce is stretched inside weekly and monthly downtrends. Even at 18x forward there's no margin of safety, because the multiple can compress further and the stop is 5% away.

My view is that MCD isn't a buy at $245. The better entries are a pullback toward $237 or lower, or a weekly close above $265.86 after Q3 confirms comps.

So my question back to you: what is the catalyst between now and $265, and why does it come before the next leg down? Bear Analyst: # Bear Closing on MCD at $245.28: We Agree on the Price, Not on Pre-Committing

You've conceded most of what your opening thesis stood on: "as good as ever," FCF acceleration, "priced in," the trade-down anchor, the monthly TD 7, the Citi target, and the $245 entry. That leaves the de-rating story, the valuation table and the bid ladder. I'll take those in turn.

What I'll give back¶

"Lower lows" was loose. The closes of $230.94 and $230.88 are a retest. The level was actually tested three times, counting the $229.20 intraday low on 10/5.
Insiders. A constant isn't a signal, and I'll stop leaning on it.
H1 funding. Financing outflow of $3.61B against FCF of $3.71B is a fair lens.
Valuation. $222 does need another ~15% compression. I'm not forecasting a collapse.

1. Your "first half of the decline" cuts against you¶

You say $334 to $284 was de-rating without deterioration, because Q1 operating income was +11.5%. But the market sold through that strength. The late-April to early-May leg, roughly $295 to $271, came when Q1's growth was the freshest fact available. I'm inferring the print timing, because the tools give no dates. If that's right, reported operating income is not what the market is paying for, and citing H1 operating income as proof of mispricing fails.

You also say I'm inferring from titles. The hard data points the same way as the headlines:

Q2 2026 YoY	Growth
Revenue	+3.7% (from +9.4%)
Operating income	+3.3% (from +11.5%)
Operating margin	47.0% vs 47.2% a year ago

Three independent headline sources say U.S. comps are softening, and consolidated numbers show the deceleration you'd expect if they were. That doesn't prove the case, but it isn't "titles only" either.

2. Your 6% growth is mostly not operating growth¶

Decomposing Q2 using the reported net income and EPS:

Step	Growth	Driver
Operating income	+3.3%	Operations
Net income	+4.8%	+1.5 pts below the line (interest, tax or other, not itemized)
Diluted EPS	+5.7%	+0.9 pts from ~0.85% fewer shares (my derivation from NI ÷ EPS)

Your valuation table assumes $13.05, which is 6% EPS growth. You told us Q1 was flattered by an easy comp, so Q2 is the better run-rate. Here is the sensitivity at Q2's operating growth:

12-month outcome	EPS	Price	Total return incl. 3.1% yield
Your base: 6% growth, 19.9x	$13.05	$260	~+9%
3.3% growth, 19.9x	$12.72	$253	~+6%
3.3% growth, 17x	$12.72	$216	~-9%

At the operating run-rate, the constant-multiple case is closer to a 6% return than 9%, for a stock that has been de-rating for eight months. The table also gives the three rows equal footing, and "the multiple stops falling" is the very thing in dispute.

3. Cash flow: wrong denominator¶

Your 1.9x dividend coverage divides OCF, which is before capex, by the dividend. Capex is 11% of revenue and rising. On FCF, coverage is 1.37x for H1 and 1.15x TTM, using your own dividend approximation. Your inference that Q2 capital return stepped up also helps me. Q2 outflow ($2.39B) exceeded Q2 FCF ($1.98B), and H1 outflow was ~97% of FCF while FCF growth is mostly base effect. Q3 2025 FCF was $2.42B, so the next print faces the hardest comp in the series.

4. The bid-ladder R/R tables aren't real¶

The 3.9:1 and 2.0:1 ratios assume a clean stop fill and a full run to $265.86. Three problems:

Gap risk. You said you can't tell whether Q3 is out. The fundamentals tool shows June 30 as the latest period. From memory, not these tools, McDonald's has typically reported Q3 in late October or early November, so a pending print is likelier than not. A -4.8% gap, like Sept. 23, from $236.70 opens near $225 and loses ~$11.80, not $7.50. That turns 3.9:1 into ~2.5:1 before any probability weighting. If Q3 is already out, show me the numbers, because nothing in the dataset has them.
Adverse selection. A bid at the midline fills when price is falling, and a pullback to $236.70 is the first leg of the bearish-resumption path. Conditional on the fill, a break of $229.20 is more likely than it is unconditionally.
The target. $265.86 is the weekly SuperTrend flip level, not a price magnet. Four overhead levels sit in between ($246.41, $250.18, $257.49 and $265.86 itself), and the technical report says none of them has been validated against past reactions. The stop is also only 1.74 ATR from $236.70, tight for a stock that moved 4.8% in a day last month.

5. "Rotations reverse" needs a trigger¶

Rotations back into defensives usually need rate relief or a growth scare. Your own data says neither is coming: Polymarket puts no cuts at 97% and recession at 8%. Your opening used the 8% as a point for MCD, but in a soft-landing tape there is little reason to pay up for defensives. Tech earnings are also drawing the attention. I see no trigger in the data for the reversal you're counting on.

Your answer to my question¶

You said you don't need to win the sequencing race, but a plan that places bids before a possible binary print is a sequencing bet. Your listed supports don't change that. The Dec. 1 flow is income demand, which you called "not a re-rating." Filling the gap and clearing $250 are price levels, and the rotation has no trigger. The only real catalyst is Q3, which you can't place in time.

Where we actually differ¶

	Bull	Bear
$245.28	Not a chase	Agree
Pre-print bids at $241 and $236.70	Yes, small size	No
Core uncertainty	U.S. comps, unknown	Same, which is why I'd wait for the number
Cost of waiting	~8% if the stock never pulls back	A few points on a good print, against avoiding an unprotected gap on a bad one

Bottom line¶

I would not buy MCD at $245.28 or pre-place bids ahead of Q3. The business is solid, but its growth is decelerating, EPS growth leans on below-the-line items, FCF coverage is thin, and the one datapoint that decides this, U.S. comps, is unknown to both of us.

I'd change my mind on: - Q3 showing U.S. comps recovering, margin at or above ~47%, and EPS growth heading toward high single digits. - A weekly close above $265.86. - After the print, a pullback to $237–$241 held above $229.20, which I'd then take as a buy.

I'd get more bearish on: - A daily close below $232.28, which flips the daily SuperTrend. - A close below $229.20, which opens $226.99 and then $216–$222 (17x on $12.72–$13.05).

Waiting for the print costs a few points if it's good. Buying before it risks a gap through your stop if it's not. Bear Analyst: # Bear Close on MCD at $245.28: Same Price, Different Standard of Proof

We agree that $245.28 isn't a buy. I'm not arguing for a short either, since a 47%-margin franchisor with a 3.1% yield and a 0.45 beta is a poor short into a possible print. The remaining gap is whether a third of a position should be at risk before Q3 is known. You asked me a fair question about thresholds, and I'll answer it below.

What I'm giving up¶

"Leans on below-the-line items" was overdrawn. Your three-period table shows Q1's headwind and Q2's tailwind largely offsetting.
The $241 rung survives a Sept. 23-sized gap, landing at $229.66 against a $229.20 stop. The gap-through problem is mostly the $236.70 rung.
I'm not forecasting a collapse. The $222 and $216 cases need another ~15% compression.

1. Your table fixes the run-rate, and $13.05 isn't it¶

EPS growth looks stable at 5.7% to 6.9%. But the gap between EPS and operating growth swung from -4.6 to +2.4 points while operating growth fell from 11.5% to 3.3%.

You say those swings are noise, and I'll accept that. Then the structural gap is H1's -0.7 points. Applied to Q2's 3.3% operating growth, EPS grows about 2.6%, or roughly $12.63. Your $12.72 assumes a zero gap, which is better than H1 actually delivered.

$13.05 is the H1 run-rate (+6.3%). Reaching it means operating growth re-accelerates from Q2's 3.3% toward H1's 7.0%. That's a legitimate bet, but it's a bet on the number neither of us has.

2. The 40% break-even uses a zero hurdle¶

Your break-even is p × (-9%) + (1-p) × 6% = 0, so p = 40%. That compares against cash earning nothing. FRED failed, so I have no verified yield, but 97% "no cuts" means cash isn't at zero. At an illustrative 4% hurdle (a placeholder, so plug in your own), the same rows give +2 and -13 points of excess return, and break-even drops to about 13%. At 3% it's 20%. A 17x outcome doesn't need to be likely to matter.

3. Drift is too small to carry the ladder¶

You said the edge has to come from drift. Here is what drift is worth against the stop distance. Assume ~25% annualized volatility (my estimate from the 1.76% ATR, not a tool output). Then the odds of reaching $265.86 before $229.20 from a $241.24 fill are:

~35% with zero drift
~36–38% with your drift
~33% break-even

That edge is roughly $1–2 a share against $12 at risk. A one-third starter makes it well under a dollar. This is smaller than the error in my volatility assumption and smaller than slippage on a close-based stop.

Adverse selection also isn't "already in the break-even column." Break-even is a hurdle, and adverse selection lowers the realized hit rate. A resting bid fills on days when sellers control the tape, and the technical report calls a pullback to the 10 EMA or midline the base case.

4. "17.8x forward" is no longer your number¶

Your Section 5 leans on 17.8x, but that uses $13.75. If that is a 2026 estimate, it needs about +23% in H2, and you've set it aside. On your own $13.05, MCD is 18.8x.

"The multiple already reflects the doubts" needs a floor, and neither of us has multiple history. A 6% bounce off the closing low also isn't an expectations gauge when the weekly and monthly SuperTrends are both still down and the daily TD 9 has completed on a possibly partial bar.

5. Your question: the thresholds¶

Q3 2025 was the hardest comp in the series: $7,078M revenue, 47.4% operating margin (the highest in the table), $3.18 EPS and $2.42B FCF.

Q3 2026 vs. Q3 2025	Buy-eligible	Stay out / sell
Revenue	≥ +5% (≥ $7.43B)	≤ +4% (about Q2's +3.7%)
Operating margin	≥ 47.4% (flat YoY)	< 47.0% (below Q2)
Diluted EPS	≥ $3.37 (+6%)	≤ $3.28 (+3%)
U.S. comp	Positive, and not slower than Q2	Negative
Guidance	Intact	Cut

Your "~47% or above" gate is too loose. At 47.0% on +4% revenue, operating income grows about 3.1%, which is your $12.72 case and not your base. The U.S. comp row is directional because the dataset has no comp history, and I won't invent a base. Mixed results mean staying out until a post-print hold above $229.20 or a weekly close above $265.86.

6. This isn't avoiding a decision¶

The decision is conditional, and now it's specified.

A pre-print starter is a bet with no information edge. Neither of us knows the comp. Event expectancy is roughly zero, and the one-third starter captures pennies of drift.
The downside branch isn't protected. Your stop is a close below $229.20, so a gap gets you out next session at whatever price prints.
The cost of waiting is real, and I accept it. A good print could gap MCD into $250–$257 supply. But a print that clears my table tells me about the one variable we both called decisive, and I'd pay that premium for the information.

Bottom line¶

I would not buy MCD at $245.28 or place pre-print bids. The business is high quality, but operating growth decelerated from 11.5% to 3.3%, the $13.05 base requires a re-acceleration nobody can see yet, and the drift edge is a few points of probability on a thin, gap-exposed setup.

The technical lines are the same as before: - A weekly close above $265.86 (+8.4%) is the first higher-tier evidence of a turn. - A daily close below $232.28 flips the daily SuperTrend down. - A close below $229.20 opens $226.99, then the $216–$222 area.

After a Q3 print that clears the table and a hold in the $237–$241 zone, I'm a buyer alongside you. Bear Analyst: # Bear Close on MCD at $245.28: The Gap Is Down to Price Discipline

We agree that $245.28 isn't a buy, that MCD isn't a short at ~19x for a 47%-margin franchise, and that Q3 comps and margin decide it. What's left is whether to commit capital before the one number we both call decisive, and whether a "mixed" print earns an add at any price or only at the right one.

What I'm giving up¶

"Stay out / sell" blurred two things. A status-quo print is "no add," not an exit signal, and I've never argued for a short. I'm relabeling my table to no-add and exit.
Your five-session hold above $229.20 is a fair minimum definition of "hold" after a mixed print.
The starter's expected value is tiny either way, under $1 a share on your numbers. My objection is about discipline, not that it moves expectancy.
You're right that my thresholds ask for improvement. I'll say why below.

1. Your "nothing changes" row smuggles in Q2's below-the-line tailwind¶

	Q3 2025	Your "Q2 rates repeat"	Q2 operating growth + H1 gap (−0.7 pt)
Operating income growth	n/a	+3.3%	+3.3%
EPS growth	n/a	+5.7%	~+2.6%
Diluted EPS	$3.18	~$3.36	~$3.26
My bucket	n/a	Mixed	No-add (≤ $3.28)

Your $3.36 needs Q3 to deliver another +2.4 points of EPS over operating growth. Your own three-period table showed that swing was the reversal of Q1's −4.6. Use the H1 gap instead and the same operating print gives about $3.26, which is the $12.63 NTM figure (12.31 × 1.026).

So $12.63 isn't a floor. It's what a status-quo operating quarter produces. The real downside sits below it: negative U.S. comps, margin slippage, or capex absorbing cash flow. A flat print supports $12.63–$13.05, not $13.0 flat.

2. Status quo is in the $245 price, not in the $237 price¶

Using your constant 19.9x and the ~$7.67 dividend, with my 4% hurdle still an illustrative placeholder because FRED failed:

Entry	Return at $12.63 ($251.6)	Return at $13.05 ($259.9)	Excess over 4%
$245.28	+5.7%	+9.1%	+1.7 to +5.1 pts
$236.70	+9.5%	+13.0%	+5.5 to +9.0 pts

A 3.5% lower entry adds about 4 points to every row. In the low case that more than doubles the excess return. That is why my bar at $245 is improvement and my bar at $237–$241 is intactness. It's one rule applied at two prices.

It also settles the add trigger. I'll accept your five-session hold, but only inside the $237–$241 zone we already agree on. I wouldn't add after a mixed print at whatever price the hold happens to occur. Adding at $245 also means buying into stacked supply ($246.41, $250.18, $257.49) on a daily TD 9 and a +1.77 z-score, and the 10/21 bar may still be partial.

3. Under your own rule, the starter is probably skipped¶

You said you'd skip the starter if Q3 is within days. From memory, not these tools, McDonald's has reported Q3 in the last days of October, and today is Oct. 21. On that basis, your rule most likely leads to my plan. I can't verify the date, so step zero is the IR calendar. If the print is already out, my thresholds table is a lookup against actuals and neither of us needs a forecast.

4. The two tails aren't equally supported¶

You say 22x and 17x both exist and neither of us can weight them. That's fair, since we have no multiple history. But the evidence isn't symmetric. The only observed trend is eight months of de-rating, and you've retired the supports for a re-rating: 17.8x forward, the rotation reversal, "priced in," and the $295 Citi target.

That isn't a forecast of 17x. It means neither tail belongs in the base case, so price has to carry the trade. At $245 the price doesn't carry it, and at $237–$241 it does.

Where we land¶

	Status
$245.28 is not a buy and not a short	Agreed
U.S. comps and margin decide it	Agreed
Post-print buy zone of $237–$241	Agreed
Five sessions with no close below $229.20 as the minimum hold	Agreed
Don't chase a good print that gaps into $250–$257	Agreed
Pre-print starter	Open, but skipped under your own rule if the print is within days
Add after a mixed print	Open: any price (you) vs. only at ≤ ~$241 (me)

Bottom line¶

At $245 you're paid about 2–5 points over cash to take a binary print on a company whose debt load neither of us can see, with $822M of cash, a 1.08 current ratio and 1.15x TTM FCF dividend coverage. At $237–$241 you're paid about 4 points more for the same risk. I'd take the second offer.

My plan, with the relabeled buckets: - Full buy: revenue ≥ +5%, operating margin ≥ 47.4%, EPS ≥ $3.37, comps positive and not slower than Q2, guidance intact. If the stock gaps into $250–$257, wait for a hold or a weekly close above $265.86. - Partial add: a mixed print (EPS $3.29–$3.36, margin 47.0–47.4%) with comps flat or better and guidance intact, after five sessions without a close below $229.20, and only at $237–$241. - No add: revenue ≤ +4%, margin below 47.0%, or EPS ≤ $3.28. - Exit or avoid: negative comps, a guidance cut, or a close below $229.20, which opens $226.99 and then $215–$222. - Technical flags: a daily close below $232.28 flips the daily SuperTrend down, and a weekly close above $265.86 is the first higher-tier evidence of a turn.

Waiting costs a few points if the print is good. Paying $245 for a status-quo print costs about as much as I'd be paid to take the risk. Bear Analyst: # Bear Final on MCD at $245.28: One Open Row, Worth About 0.3 Turns of P/E

We've converged. We agree that $245.28 isn't a buy and isn't a short, that U.S. comps and margin decide it, that there's a five-session hold above $229.20, and that neither of us chases a gap into $250–$257. Only the mixed-print ceiling ($245 vs. $241) is open. Before that, here is what I'm giving up, including a flaw in a table I built.

What I'm giving up¶

Your event-premium point is coherent. After the print resolves, the same arithmetic buys a position whose main unknown is gone. I won't claim the premium disappears.
Pre-print behavior is settled. Alerts and no orders is my plan too.
"No re-rating needed" holds at $245. The 5.7–9.1% there is EPS growth plus yield.
I overstated "three sources" on comps. Only two headlines (Zacks, Simply Wall St.) address softer U.S. comps, and neither gives a figure. The third was an ETF-flow item.

1. The ceiling grid is a mean-reversion table, and I built it¶

Our grid fixes the 12-month exit at 19.92x for every entry. If the multiple stays constant relative to your entry, every entry earns the same EPS growth plus yield, about 5.7–9.1%. The extra points in the lower rows come from assuming the stock bounces back to 19.92x, which neither of us forecasts. My earlier claim that $237 pays "4 points more" for the same risk overstated it.

The case for a lower ceiling still holds as cushion. A cheaper entry improves every outcome by about the same amount (EPS $12.63, $7.67 dividend, round-number entries):

12-month exit	Price	From $245	From $241	Difference
17x	$214.7	−9.2%	−7.7%	1.5 pts
19.92x	$251.6	+5.8%	+7.6%	1.8 pts
22x	$277.9	+16.6%	+18.5%	1.9 pts

The $4 gap is 0.32 × $12.63, or about a third of one P/E turn. Your $245 low case clears my 4% placeholder by 1.7 points. That placeholder is unverified because FRED failed, and a third of a turn of multiple wipes out the cushion. With no multiple history, no debt data and an eight-month de-rating, when the cushion is smaller than the error in every input I'd take the cheaper number. It costs only fill probability.

If a mixed print, five clean sessions and a $245 tape show up, a partial buy isn't an error I'd litigate. It's a 1.6% price gap, and I'd rather be paid for it.

2. A number we both lean on doesn't reconcile¶

The $6.26B TTM FCF underlies the 3.6% FCF yield and the 1.15x coverage we've both quoted. But Q3 2025 ($2,417M), Q1 2026 ($1,730M) and Q2 2026 ($1,976M) already sum to $6,123M. If the vendor TTM is on the same basis, Q4 2025 FCF was about $0.14B.

That's either a near-zero quarter neither of us has discussed or a vendor figure on a different basis. It cuts both ways. A normal Q4 would make coverage better than 1.15x, and a truly weak one would be a warning sign. The next report doesn't resolve this, but the filing does. I'd reconcile it before sizing, alongside debt and interest coverage.

3. Score the print on operating income, not EPS¶

EPS is the noisiest row. Its gap to operating growth swung from −4.6 to +2.4 points in two quarters. When rows disagree, I rank them: guidance and U.S. comp, then operating income and margin, then revenue, then EPS. Q3 2025 operating income was $3,357M, so my thresholds translate to:

Bucket	Operating income	Implied YoY
Buy-eligible	≥ ~$3.52B (revenue +5% at 47.4%)	≥ +5%
Mixed	~$3.46–3.52B	+3% to +5%
No-add	< ~$3.46B (revenue +4% at 47.0%)	< +3%

EPS within a couple of cents of $3.28 is a tie, not a signal. Comps and margin break it.

4. Why not today, in one table¶

Factor	Evidence
Binary event	Q3 is likely within ~2 weeks (from memory, unverified). U.S. comp, guidance and debt are all unseen.
Growth	Operating growth slowed from +11.5% to +3.3%. $13.05 needs re-acceleration, and status quo gives about $12.63.
Tape	Weekly and monthly SuperTrends are down, and the 200 SMA is falling. The daily TD 9 and +1.77 z-score are stretched, and the 10/21 bar may be partial.
Supply	$246.41, $250.18 and $257.49 sit between price and the $265.86 weekly flip.
Consumer and macro	Two headlines on softer U.S. comps, a "$5 large fry" backlash, $4.33 gas headlines, and 97% no cuts in 2026.

Where we land¶

	Status
$245.28 is not a buy and not a short	Agreed
Pre-print: alerts only, no orders	Agreed
Thresholds with no-add and exit buckets	Agreed
Five sessions with no close below $229.20	Agreed
Don't chase a gap into $250–$257	Agreed
Mixed-print add ceiling	Open: $245 (bull) vs. $241 (me), about 0.3 turns of P/E

Bottom line and plan¶

MCD is a high-quality franchise at a fair price, with a decelerating growth rate and an unseen balance sheet. The bull's constant-multiple return is real but thin, and one third of a P/E turn erases the difference between our ceilings. The cheaper price is the better trade for the same risk, and committing capital before Q3 is a bet neither of us has an edge on.

Today: No position. Set alerts at $241, $236.70, $232.28, $229.20 and $265.86. Check the IR calendar. Reconcile Q4 2025 FCF and pull debt and interest coverage.
Full buy: Revenue ≥ +5%, operating margin ≥ 47.4%, operating income ≥ ~$3.52B, comps positive and not slower than Q2, guidance intact. If the stock gaps into $250–$257, wait for a hold or a weekly close above $265.86.
Partial add: A mixed print (operating income +3% to +5%, margin 47.0–47.4%) with comps flat or better and guidance intact. It needs five sessions with no close below $229.20, at or below $241 (I'd tolerate $245).
No add: Operating income below +3%, margin below 47.0%, or revenue ≤ +4%.
Exit or avoid: Negative comps, a guidance cut, or a close below $229.20, which opens $226.99 and then the $215–$222 area.

Waiting costs a few points if the print is good. Paying $245 for a status-quo print earns about as much as the risk deserves, and at $241 the cushion is at least visible.

Research Manager¶

Recommendation: Hold

Rationale: The two sides ended up close. Both agree MCD at $245.28 is not a buy and not a short, and that Q3 U.S. comps and operating margin decide what comes next. So the question was which side's framing should drive what we do now, and on that the bear won most exchanges.

The bull's strongest point stands. H1 2026 revenue rose 6.4%, operating income 7.0% and EPS 6.3%, while the stock fell about 27% from $334.50. Roughly half of that drop came while earnings were still growing. The franchise also remains high quality: 46.5% operating margin, $6.26B TTM FCF, a 3.1% yield, a 0.45 beta, and a narrowing equity deficit. The technical base is real too, with closes of $230.94 and $230.88 forming a double bottom after a heavy-volume selloff and an RSI washout.

The bull then gave up most of the supports for buying now: - The 18% FCF growth was mostly a Q2 base effect, and Q1 FCF fell 7.8%. - 17.8x forward depends on $13.75, which needs about +23% H2 growth if it is a 2026 figure. On $13.05 the stock is 18.8x, and on a status-quo $12.63 it is 19.4x. - 'Priced in' rates, the rotation reversal, the trade-down argument and the Citi $295 target were all retired. - Dividend coverage is about 1.15x TTM FCF, not 1.9x. - The pre-print starter was dropped.

The bear's points held up: - Q2 slowed to +3.7% revenue and +3.3% operating income, with margin at 47.0% versus 47.2% a year earlier. A status-quo operating quarter implies about $3.26 Q3 EPS and $12.63 NTM, not $13.05. - Weekly and monthly SuperTrends are down and the 200 SMA is falling. - Overhead supply sits at $246.41, $250.18, $257.49 and $265.86. - Cash is $822M with a 1.08 current ratio, and debt and interest coverage are unseen. - The edge from drift is under $1 to $2 a share against about $12 of stop risk, ahead of a likely binary print.

The bear also ran the honest math showing the constant-multiple return is about 5.7% to 9.1% from any entry. A cheaper entry adds cushion, about a third of a P/E turn between $241 and $245, not extra return.

If the bear won on process, why not Underweight? Because the bear never argued for trimming or shorting. Both sides call this a quality franchise at roughly fair value, and no exit trigger has fired: price is above $229.20, there is no negative comp data, and there is no guidance cut.

The evidence on the one variable that matters, U.S. comps, is missing for both sides. Several other gaps are also unresolved: - the Q3 report date - debt and interest coverage - the 10-year yield (the FRED pull failed) - whether the forward EPS figure is for 2026 or 2027 - an implied Q4 2025 FCF of only about $0.14B, which needs reconciling - multiple history

That is the 'too thin to call' condition, so the decision is Hold. Keep existing exposure, commit no new capital before the print, and pre-commit to the bear's threshold table to decide afterward.

Strategic Actions: Step 0, before trading: - Check the McDonald's IR calendar for the Q3 2026 date. From memory, not tool data, it is likely between late October and early November. If Q3 is already out, score the actuals against the table below. - Pull total debt and interest coverage. - Reconcile vendor TTM FCF ($6.26B) against the quarterly sum ($6.12B), which implies about $0.14B for Q4 2025. - Do not size above half a standard allocation until those three are checked.

Pre-print positioning: - If flat, open no position and place no resting bids. - If at or below a standard allocation, maintain it. - If above a standard allocation, trim to standard before the print. A Sept. 23-sized gap (-4.8%) or an 8% gap (about $222 from $241) should be a tolerable loss. - Set alerts at $241, $236.70, $232.28 (daily SuperTrend flip), $229.20 (exit level) and $265.86 (weekly SuperTrend flip).

Post-print scoring rules: - Score metrics in this priority order: guidance and U.S. comps first, then operating income and margin, then revenue, then EPS. - Treat EPS within a couple of cents of $3.28 as a tie and let the higher-priority metrics break it. - Q3 2025 comparison figures: revenue $7,078M, operating margin 47.4%, operating income $3,357M, EPS $3.18.

(1) Buy-eligible print: - Conditions: revenue at or above +5% (about $7.43B or more), operating margin at or above 47.4%, operating income at or above about $3.52B, EPS at or above $3.37, U.S. comps positive and not slower than Q2, guidance intact. - Action: build toward a full standard allocation, roughly a third immediately on a hold above the prior day's low, with the rest scaled into $237–$241. - If the stock gaps into $250–$257, do not chase. Complete only after a multi-session hold or a weekly close above $265.86, which would justify revisiting the rating at Overweight.

(2) Mixed print: - Conditions: operating income up 3% to 5% (about $3.46B–$3.52B), margin 47.0%–47.4%, U.S. comps flat or better, guidance intact. - Action: after five sessions with no close below $229.20, add up to about half to two-thirds of a standard allocation using limit orders at $241 or below. $245 is an absolute ceiling, but prefer $241 for cushion against unverified inputs.

(3) No-add print: - Conditions: operating income below +3%, margin below 47.0%, revenue at or below +4%, or EPS at or below $3.28 without offsetting comp strength. - Action: no new money. Existing holders may stay at standard weight or less, and should cut to half a standard allocation on a daily close below $232.28.

(4) Exit or avoid: - Triggers: negative U.S. comps, a guidance cut, or a daily close below $229.20. - Action: exit and move to Underweight or Sell. Downside targets are $226.99, then $215–$222, which is 17x on $12.63–$13.05.

Execution notes: - The stop is close-based, so size for gap risk rather than stop distance. - Take partial profits into $250.18 and $257.49 resistance on any post-entry rally. - Treat the 10/21 bar, the daily TD 9 and the +1.77 z-score as possibly unreliable, because the bar may be a partial print.

III. Trading Team Plan¶

Trader¶

Action: Hold

Reasoning: The research plan's Hold fits the price structure. MCD at 245.28 sits in a daily counter-trend bounce, with the weekly and monthly SuperTrends still down (weekly stop 265.86), a falling 200 SMA at 282.01, and overhead supply at 246.41, 250.18 and 257.49. The daily TD 9, the +1.77 daily z-score and price near the upper Bollinger Band argue against chasing, though the 10/21 bar may be partial. The quality franchise and the 230.88 double-bottom base argue against trimming or shorting, and no exit trigger has fired. The deciding variables, Q3 U.S. comps and guidance, are unseen, and debt, interest coverage and the Q3 date are unverified, so the evidence is too thin to commit new capital before the print. Any later add should be a limit order near 241, close to the 10 EMA at 241.24, to leave a cushion.

Entry Price: 241.0

Stop Loss: 229.2

Position Sizing: Keep existing exposure and add nothing before the Q3 print. If flat, open no position and place no resting bids. If at or below a standard allocation, hold it. If above standard, trim to standard. Do not size above half a standard allocation until the Q3 date, debt and interest coverage, and the FCF reconciliation are checked. After a mixed or better print, scale in with limit orders at 241 or below, starting at about a third of a standard allocation. Cut to half on a daily close below 232.28 and exit on a daily close below 229.20.

FINAL TRANSACTION PROPOSAL: HOLD

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Neither of the other two analysts has spoken, so I'll take on the arguments I expect from them. The Hold is right, but I want to explain why it's an aggressive call and not a timid one.

Start with what the market has already done to MCD. The stock fell about 31% on a closing basis, from 334.50 to 230.88, while H1 2026 EPS grew about 6.3%, operating margin held near 47%, and H1 free cash flow rose about 18%. The multiple went from roughly 28x in February to about 20x trailing and under 18x forward. The stock has repriced from premium defensive compounder to something close to a broken story, while the earnings engine kept running. That is where asymmetry comes from. The 16.6M-share flush on 9/23 and the 11.4M-share reversal on 10/8 look like forced selling meeting real buyers. OBV has already retraced its late-September drop while price has recovered only about 74% of it. Money is coming back faster than the price shows.

Now the conservative case. I expect them to lead with the weekly and monthly SuperTrends being down, the falling 200 SMA at 282, and the 50 below the 200. All true, and the plan respects it by refusing to chase. But treat that as a reason to avoid positioning now and you'd only buy once the weekly stop at 265.86 breaks. That is about 8% above here and more than 10% above the 241 entry. By the time the higher timeframes confirm, most of the repair is gone. The monthly z-score of -1.78 and the 7-of-9 monthly buy setup say the longest timeframe is maturing to the downside. Trend followers will always be late, and the plan buys the pullback and manages risk with defined levels.

They'll also cite the insider selling, about $40.5M and no buys. But the sales came at $280 to $333, mostly after option exercises, and Erlinger's look like a scheduled plan. Nobody has sold since June, so no insider has sold near 245. The absence of buying is not confirmation of anything. It's a non-signal, and I won't build a thesis on it in either direction.

They'll point to the slowing U.S. comps, the affordability backlash, and the 97% odds of no Fed cuts. The comp slowdown is real, and Q2 revenue growth slowed to +3.7%. But "no cuts in 2026" at 97% is consensus, not news. The stock has de-rated into that backdrop, and an 8% recession probability means no demand collapse is priced in. The negative headlines are everywhere in the sentiment data, which tells me the bad news is crowded. A mixed print into a 17.8x forward multiple and a 3.1% yield could be a relief event. I'd also flag that the 1.15x dividend coverage and the PEG are rough derived numbers, not hard facts. I'm not leaning on the unverified Citi $295 target either, because it's retail hearsay.

The neutral analyst will say Hold is obviously fine and stop there. I'd push on that. Hold is correct because the daily TD 9, the +1.77 z-score, price pressed against the 246.41 upper band, and a flattening MACD histogram say the bounce wants a rest. The aggressive move is to let the market come to us. The 10 EMA at 241.24 and the Bollinger midline at 236.70 sit right where the 2x ATR stop reference lands, and the daily SuperTrend at 232.28 lines up with the 3x ATR stop. From 241 with the 229.20 stop, risk is about 11.80. A move to 257.49 pays about 1.4R, 265.86 about 2.1R, and a return toward the falling 200 SMA about 3.5R. That's a strong payoff for a low-beta name with a 47% operating margin.

Where I'd lean harder than the plan is the execution after the print. A third of a standard allocation is a fine first step, but if Q3 comes in mixed or better and guidance holds, I'd want the plan to scale quickly to a full allocation. The real risk is gapping through 241 on good news and sitting out the repair, and the plan should accept that cost without hand-wringing. The stops are already defined: cut half below 232.28, exit below 229.20.

Finally, I wouldn't ignore the data holes. We don't have the Q3 date, the comp number, guidance, debt, or interest coverage, and the 10/21 bar may be partial. That is exactly why the plan sizes small before the print and big only after the evidence arrives. Cutting risk on a quality franchise at the low would be selling the bottom of a de-rating. Adding before the print would be gambling on a number we haven't seen. Holding with a loaded limit plan, tight exits, and the willingness to press on a good print is the high-reward path. Aggressive Analyst: Let me give back what I should first, because you each landed a real hit.

Neutral is right that my R-multiples were measured from a 241 fill that only exists after the print. Conservative's were measured from 245 that nobody proposes to buy. Neutral is also right that "crowded bad news" was an overreach. A 5.2 at low confidence, with Reddit missing and 9 tagged posts out of 30, is close to no reading, not a washout. And the forward multiple is softer than I treated it. If the $13.75 is calendar 2026, then using the report's derived Q4 of about $3.03, the second half needs EPS growth of roughly 23%. So I'll drop "under 18x" and use the trailing figure instead. That is about 19.9x against roughly 28x in February, still about eight turns of compression while EPS grew.

That leads to Conservative's estimate-cut math, which I think cuts the other way. Even if a mixed print trims growth to 6% and forward EPS to about $13.05, the multiple moves from 17.8x to 18.8x. That is one turn, against the eight the market has already taken. I'm not calling this cheap, since the PEG of 2.57 says it isn't. My claim is narrower: the stock has already paid a lot for deceleration, so a mixed print has less left to take away than it did in February. The stops handle the case where I'm wrong.

On gap risk, Conservative's "size for the gap" is right for existing exposure, and I won't argue it. But for new money the plan already solves it. Nothing goes in before the print, so the earnings gap, and the kind of 4.8% day we saw on 9/23, happens while we're not adding. That is the case for being flat into the print.

Conservative's contradiction charge also misreads me. I never proposed buying a gap to 255 with a 229 stop. The limit sits at 241 or below, and "accept the gap cost" means don't chase. Neutral's fix is right, though: any tranche bought higher should carry a stop set against its own entry, not inherit 229.20.

On the limit filling "when the market is moving against you," that is what a pullback limit is for. Conservative says the short-term base case is a pullback toward the 10 EMA and the midline, because of the daily TD 9 and the flattening MACD. If you believe that, you want the order waiting there after a clean print, not chasing 246 to 250. His argument supports the entry.

On trimming existing exposure to half, I side with Neutral and add a point. The TD 9 and the +1.77 z-score sit on a bar with 2.57M shares against a normal 4 to 6M, so they're provisional. Selling half on that, with no exit trigger fired, means you may sell inside the 246 to 250 supply zone and then rebuy higher if the print is fine. The plan caps new money at half because we're blind. Existing money was underwritten earlier, and selling and rebuying costs more than not buying.

On the monthly 7-of-9, I wasn't using it for timing. It says the longest timeframe is maturing, not that a low is in. On macro, I agree rate relief isn't coming and the 8% recession market is thin. My point was that the multiple has already de-rated into no cuts, so it doesn't need relief, only no new shove. On FCF, Neutral is right that H1 against H1 compares four reported quarters, so it's firmer than the 1.15x coverage. I'll treat both as directional: cash flow is growing and the cushion is thin.

Where I still disagree is the ceiling. Conservative wants the half cap until the weekly SuperTrend turns. Neutral wants it lifted on a close above 257.49. Both gates sit in the supply zone, so most of the position would be built above 250. Conservative's own math shows what that costs: buying near 255 pays roughly 11 points to the weekly stop against 26 of risk. The weekly stop is also a moving target. By construction a SuperTrend ratchets down while the trend is down, so 265.86 can fall toward price over time. That is my inference from how the indicator works, not something the report states.

Most of what the half cap guards against, namely the Q3 date, debt, coverage, comps, guidance and the FCF reconciliation, gets answered by the release and the filing, not by price. So lift the cap when those checks come back clean, and let price confirmation govern only the adds above the pullback zone.

Concretely, using Neutral's "define it before you see it" test (margin near 46 to 47%, no guidance cut, nothing ugly on debt or coverage, and the daily SuperTrend at 232.28 holding after the reaction), I'd buy a third at 241. Then I'd put a second third near the 236.70 midline, with the stop at 229.20. A blended entry of about 238.85 puts risk near 9.65 points, below the 11.80 from 241 alone. From there 257.49 pays about 1.9R, 265.86 about 2.8R, and the 200 SMA a bit over 4R at today's level, less as it keeps falling. The final third waits for closes above 250.18 that hold a retest, with its own stop. If the stock never pulls back, I don't get filled and I accept that, which is the cost Neutral asks me to own.

Conservative closes by saying that if I'm wrong, I'm full-sized in a falling-200-day, lower-high stock. In this plan nothing is sized before the print. The position gets halved on a close below 232.28 and exited below 229.20, which is roughly a 4% loss from the blended entry. Missing a base also has a price, and a staircase that buys mostly above 250 pays it every time. I'm backing the Hold, because on current evidence it's the right call before the print. The difference is that I want the order book ready for the pullback after it. Aggressive Analyst: I'll take the hits first, because most of what Conservative and Neutral said about my ladder is right.

The drop from 11.80 to 9.65 points of risk was a per-share comfort number. The position was twice as big, so dollar risk to the 229.20 stop rose about 64%. The 236.70 slice also sat about one ATR above my own cut-half trigger at 232.28. A rule set that buys at 236.70 and trims at 232.28 argues with itself, so I'm dropping that bid. If I ever want a second bid below the first, it has to come out of the same risk budget, not on top of it.

I'll also drop "underwritten earlier." Neutral's right that it's sunk-cost thinking. The test for existing size is whether an 8% gap to the mid-220s is tolerable. If it isn't, trim the excess with limit sells in the 246 to 250 zone. The dividend hook is out too. About $1.92 a quarter doesn't matter against a stock that fell 4.8% in a day.

On the multiple, "eight turns" leaned on a February peak, and the report has no multiple history. A better anchor is that the stock was around 287 a year ago and is 245 now, down about 15% while trailing EPS is higher. Neutral's rough estimate of four to five turns of compression is fair. I'm not calling that a cushion, because an unexplained decline is a risk. My narrower claim stands: a mixed print has less left to take away than it did in February, and the stops cover me if I'm wrong.

The selection point is Conservative's best one against a limit at 241, but it overreaches. The bid isn't blind. It only goes live after the checks come back clean, and a close below 232.28 means I'm not in. A soft tape that holds the 10 EMA zone and 232.28 is information. The alternative isn't free of selection either. Buying strength into 250 to 257 means buying where everyone who bought near the 250.35 close on 9/22 is hoping to get out, with the weekly stop only 8 to 16 points overhead. The technical report calls a pullback to the 10 EMA or midline the base case. I'd rather pay for the expected move with a defined exit than for the unexpected extension at a worse price.

On gap risk, I take Neutral's point that fat tails cut both ways. Conservative's 1.4R only applies to the losers that gap, and the real control is sizing to the gapped loss, which is cheaper on a third than on a full position.

That leaves two small disagreements.

The first is what lifts the half cap. The plan set it at half because of the Q3 date, debt, coverage, and the FCF reconciliation, and those are all information gaps. The release and filing close them. So I'd move from a third toward half on clean checks plus a daily close holding above 232.28. Conservative is right that clean information isn't market acceptance, which is why I keep the price condition and don't jump straight to standard. Price gates should govern everything beyond half, including the step to two-thirds on a close above 250.18 and the step to standard above 257.49. That's about a sixth of a standard position of difference between Neutral's staircase and mine, and I'd rather say so than dress it up.

The second is the shape of the staircase. Neutral said the later tranches pay about 1.5R to the weekly stop and under 1R to the 257 shelf, so they buy confirmation and not payoff. If that's right, equal slices up the staircase are the wrong shape. The asymmetry sits in the first tranche, so on clean checks it should be a third and not a default quarter, and later tranches should be smaller. If the pullback never comes and the stock reclaims 250.18 and holds a retest, a quarter there is fine. I'll own the cost of missing the pullback.

Everything else we've converged on. Add nothing before the print and place no resting bids. Run the gap test on existing exposure. Define "clean" in advance: operating margin near 46 to 47%, no guidance cut, nothing ugly on debt, coverage, or the financing outflow, and U.S. comps not materially worse than the headlines imply. Anchor the post-print bid to the post-reaction 10 EMA and daily SuperTrend, not to this week's numbers. Give each tranche its own stop under its own retest low, and cap the total at standard until the higher timeframes change.

Look up the Q3 date first. McDonald's has historically reported somewhere between late October and early November, but that's my memory and not in our data. It decides whether "before the print" means days or weeks, and a stock that's pulled back to the 10 EMA two weeks before earnings is a much harder bid to leave unfilled.

I still back Hold. The plan stays flat while the key numbers are unseen, and it commits when the information arrives, not weeks later when price has done the confirming and the payoff is down to 1R. That timing is where the staircase and the ladder differ, and it's why I'd front-load the one tranche that has real asymmetry. Aggressive Analyst: Conservative, Neutral, you've talked me out of most of my ladder, so I'll say what I'm giving up, what I'm keeping, and the one thing I'd still fight for.

Conservative is right that a clean test built on operating margin doesn't discriminate. Margin sat at 45 to 47% all the way down and the stock still lost 31%. His EPS arithmetic holds, and I'll push it a step further. By the report's own quarters, 2025 EPS was about 11.95. Run-rate growth of 6.3% gives roughly 12.70 for 2026, which puts the stock near 19.3x, not 17.8x. So on a run-rate print the stock isn't cheap, and I'm done using valuation as the cushion. My case rests on defined exits and on what the tape tells us after the print, not on a low multiple.

I'll take Neutral's definition of clean as "no worse than run rate." A run-rate print earns a quarter. A result above run rate with a reaction that holds earns a third. That settles quarter versus third.

You're also both right about 232.28. It's where the plan cuts half, so using it as the gate to lift a cap is circular. And Conservative's 0.8R to the first shelf is correct, so I retract "real asymmetry." What's left of the first tranche's case is narrower. The stop is cheap relative to the entry, and it's bought into weakness after the information arrives, not into the 250 to 257 supply zone. The 229.20 stop is about 2.7 ATR from 241, already past Conservative's two-ATR floor. Neutral's amendment is right too: if the open-risk budget gets tight, shrink the add and don't tighten the stop.

I like the open-risk cap more than you might expect. Paying for adds by trailing earlier stops up is pyramiding, which is the aggressive trader's discipline: add to what's working, never to what's falling. Once the first tranche is validated by a close above 250.18 and a retest, its risk is mostly released and can fund the next tranche. I'd set that size by the gapped-loss test, not a fixed fraction. And if the stock never gives a retest, I accept missing it.

The premise check is the best contribution here, and I agree it goes first. My memory says late October and Conservative's says early October, so neither counts, and a calendar lookup settles it. If the print is already behind us, that helps the plan. The blind-spot reason for the half cap disappears, you read the release, and the first bid goes at the post-reaction 10 EMA now, with no waiting.

The 9/23 homework matters for the same reason. My "forced selling meeting real buyers" line was an inference, and I'll own that. If peers and the index fell that day, it gains some weight. If it was company-specific, "clean" has to answer that specific problem, and the first tranche drops to a quarter and waits for 250.18. I'd rather say now what would change my mind than discover it afterward.

I'd also rank the homework. The Q3 date and the 9/23 news change the plan. The 10-Q debt and coverage check and the FCF reconciliation are veto checks. I expect them to come back fine for a company like this, but that's an expectation, so run them. Re-running the daily readings once the 10/21 bar is final is routine. My worry is that this plan now has so many gates it can't be wrong, and so can't make money either. The point of the work is to act the day it's done.

Hold stands. Before the print, add nothing and place no bids. Existing size passes the 8% gap test or gets trimmed with limit sells in the 246 to 250 zone. What I'd still fight for is putting the first tranche in at the post-reaction pullback on the day the checks are complete, not after several more closes, and sizing it to the reaction. The cost of being wrong is modest. A third of a standard position stopped at 229.20 loses about 4.9% on that third, under 2% of a standard allocation, and roughly 2% even if it gaps to the mid-220s. The cost of the fully confirmed version is also known: buying near 251 with a stop around 243, and paying about 10 points of entry price for the shelf having cleared. Neutral says that buys probability, and I agree it buys some. I'd rather own both tranches, the cheap one first and the confirmed one second, than only the expensive one. Aggressive Analyst: Conservative, Neutral, most of what you added this round is right, so I'll take those points first and then say where I still disagree.

On timing, one full post-print close costs about a day, and I'll pay it. I was treating "the checks are done" as the trigger, but part of "clean" is whether 232.28 and the 10 EMA zone hold, and you can't know that intraday on reaction day. Neutral's single exit for new money is also correct. A cut-half trigger at 232.28 and an exit at 229.20 are 3.1 points apart, less than one ATR of 4.31, so for a fresh tranche they're one decision. I'd put one stop at structure, measure the two-ATR floor off the post-reaction ATR, and let a wider stop mean a smaller position. The staged cut stays for legacy exposure only. I also agree that beta of 0.45 shouldn't relax anything, since the stock lost 31% at that beta. The sizing language should be in loss units, because we can't see the caller's book. Run the gap test, and if an 8% drop to the mid-220s isn't tolerable, trim the excess with limit sells in the 246 to 250 zone. I'm also fine with the re-entry lock. After a stop-out, no new money until 250.18 is reclaimed and retested.

First disagreement: Conservative, I'd drop the hard $3.55 bar. Neutral is right that the market grades against consensus, and it's softer than that. We don't know what period the $13.75 covers. If it's calendar 2026, then with the report's derived Q4 of about $3.03, the second half needs about $7.65 against roughly $6.21 last year, which is 23% growth. Q3 would have to be near $3.90. If it's a forward twelve-month figure, $3.55 is only a loose proxy. A rule requiring a print to "clearly clear both numbers" could be one that no realistic print clears, and then the third-of-standard tier never fires. Use $3.37 and $7.34B to screen out bad prints, and let the reaction be the veto. A stock that's down 31% and holds 232.28 and the 10 EMA after a run-rate print is giving information no EPS threshold can.

Second, the re-entry lock makes the first tranche a one-shot, so don't make it a token. With a lock in place, an undersized first tranche pays the full cost of a locked-out regime and captures little if you're right. That's why I want a third when the print is above run rate and the reaction holds, and a quarter when it only meets run rate. The gap test caps both. Stopped at 229.20 from 241, a third of a standard allocation loses about 1.6% of the standard position. That's a cheap attempt, so make it a real one.

Third, a challenge to Neutral's cost-of-confirmation fix. A tranche near 251 with a stop around 243 is 8 points of risk, which is about 1.9 ATR at today's 4.31. That's under the two-ATR floor Conservative set, and I agree with that floor. So the confirmed tranche either gets a wider stop and a smaller size, or it has the same earnings-week whipsaw problem as an early entry. I think the staircase is still right, but the confirmed tranches are smaller and slower adds, not a substitute for the first one. The first tranche is the only one whose stop, about 2.7 ATR from entry, sits below structure instead of inside the 246 to 257 supply shelf.

I'd also state plainly what we give up. If the print is fine and the stock gaps to 255 or so and never returns to the 10 EMA, we're flat until a 250.18 retest, and then we hold a quarter. From 241 to the weekly stop at 265.86 is about 10%. From 251 it's about 6%. We forgo roughly four points of a ten-point move. I accept that price, and I'd rather say it now than rationalize it afterward.

Finally, the gates are only cheap if the homework gets done. The print date is the one fact that changes which branch we're on, and the 9/22 to 9/24 news check against peers and the index changes what "clean" has to answer. The 10-Q debt and coverage check and the FCF reconciliation are veto checks, so run them today. The date tells us how long we wait, not what we do. I said at the start that adding before the print is gambling on a number we haven't seen, and a distant print date doesn't change that.

So I'm at Hold on the same three live questions Neutral named. Which branch are we on, the print ahead or behind? Is existing size survivable at an 8% gap? Did the first post-reaction close hold 232.28 with the checks clean? If all three come back clean, we commit a real first tranche at the post-reaction pullback, with one exit and defined risk. We add only as price pays for it, and we stay capped at standard until the weekly trend turns. The edge here isn't being early. It's having every number defined before the information arrives, so we can act the day it does.

Conservative Analyst¶

Conservative Analyst: Hold is the right label, but I don't think the aggressive analyst's reasons for it are sound, and I'd tighten the plan.

Start with the asymmetry argument. The stock fell 31% while EPS grew 6.3%, and that is exactly what a market does when it stops believing the growth rate will last. Q1 revenue growth of 9.4% was flattered by an easy comparison, and Q2 slowed to 3.7%. The 17.8x forward multiple rests on $13.75 of forward EPS, which implies about 11.7% growth when the business just delivered 5.7% in Q2. If a mixed print trims that estimate to around 6% growth, forward EPS is closer to $13.05 and the multiple is nearer 18.8x. A mixed print is also what the Zacks and Simply Wall St. headlines are already pointing toward, so I don't see that as a relief setup. The "forced selling meeting real buyers" story is an inference too. Our own tools say they can't explain the 9/23 move.

On R-multiples, the aggressive analyst quotes payoffs from a 241 entry that hasn't been filled. From today's 245.28 with the 229.20 stop, risk is about 16 points. Reaching 257.49 pays under 0.8R, 265.86 about 1.3R, and the 200 SMA about 2.3R. Even that 200 SMA target keeps moving, since the average dropped about 7.5 points in the last month. All of that sits under the 246.41 band, the 50 SMA at 250.18, and the 257.49 peak, with the weekly and monthly trends down. Lining up a stop with an indicator doesn't make the level hold. The technical report says none of these levels has been validated as support. It only makes the loss computable, and only if you get the fill. An earnings gap can blow through 232.28 and 229.20 in one session. This stock already dropped 4.8% in a day on 9/23.

His plan also contradicts itself. He says to scale to a full allocation quickly after a good print and accept the gap cost without hand-wringing. But if the stock gaps to 255 or so, you're buying into the 250 to 257 supply zone with a 229 stop. That is about 26 points of risk for roughly 11 to the weekly stop, and the asymmetry he's selling is gone. A limit at 241 also tends to fill when the market is moving against you, which is the pullback scenario that the daily TD 9 and the flattening MACD already favor.

On the "selling the bottom" line, the low was 230.88 on 10/7. We're 6% above it, sitting at the top of the Bollinger range after a completed daily 9. Trimming here is not selling the low. And a base only counts once it clears overhead supply, which it hasn't.

His read on the monthly signals mixes time horizons. The monthly TD count of 7 needs two more monthly bars, and the technical report calls it a months-long watch, not an imminent signal. You can't use that to justify buying in the next few weeks around an earnings print.

On sentiment, I don't see crowded bad news. The score is a mixed 5.2 out of 10 with low confidence, Reddit is missing, and only 9 of 30 StockTwits posts are tagged. Of those, retail leans 2 to 1 bullish, with calls for $270 and a promotional options bot. That reads as dip-buying, not a washout, and it's not a contrarian signal. The macro point also misses the issue. A 3.1% yield on a stock facing a 97% no-cuts regime means rate relief isn't coming to rescue the multiple. The 8% recession probability is a thin $2.3M market, and the real risk is a slow value-perception problem with lower-income traffic, not a collapse. We also have no hard macro data because FRED failed.

I'll agree with him that insider selling is weak evidence. Most of it followed option exercises, Erlinger's looks scheduled, and insiders are likely in a blackout before earnings anyway. I'm not building a case on it.

He's also selective about which numbers to doubt. He dismisses the 1.15x dividend coverage as rough, but then leans on the 18% H1 FCF growth. That figure comes from quarterly rows that don't reconcile with the $6.26B TTM number, since the three reported quarters sum to about $6.1B and imply a tiny Q4. Both are derived. Meanwhile cash is $822M, the current ratio is 1.08, financing outflow doubled in Q2, capex is up 17%, and we have no debt or interest coverage data. McDonald's is very likely fine on leverage, but "very likely" is not verified.

So I'd keep Hold with these adjustments:

Apply the plan's own half-allocation cap to existing exposure. The plan won't commit new money above half a standard allocation because of the data holes, yet it lets existing holders ride through the same holes up to a full allocation. I don't know your holding, but whatever it is, I'd trim anything above half standard into the 246 to 250 zone before the print. That's a risk-budget call, not a bearish one.
Size for the gap, not the stop distance. Assume an earnings move of 5% or so through the stops and make sure that loss is tolerable.
Don't let the print alone trigger the scale-up. Start the post-print add at a quarter allocation, not a third. Add further only after closes above the 50 SMA and 257.49 with 241 holding, not on a pre-committed schedule.
Keep the half-allocation cap in place until the weekly SuperTrend turns. Checking debt and coverage fixes an information gap, but it doesn't fix a trend regime that's still down.

If we're wrong on this, we give up some upside. If the aggressive analyst is wrong, he's full-sized in a falling-200-day, lower-high stock when the print disappoints. Conservative Analyst: Aggressive, you gave ground on the R-multiples, the sentiment read and the forward multiple, so I'll do the same where I overreached. Holding the half cap until the weekly SuperTrend turns at 265.86 was too slow a gate. Neutral is right that most of what the cap guards against is information, and the release and filing supply that. I also won't lean on the daily TD 9 or the +1.77 z-score, since both sit on a 2.57M-share bar that may be partial. And you and Neutral are right that H1 against H1 FCF is firmer than the 1.15x coverage figure.

My trim point was never about the TD 9, though. It was about the plan being inconsistent: it won't let new money exceed half a standard allocation because of the data holes, yet it lets existing money ride at full size through the same holes. "Existing money was underwritten earlier" is the weak part of your answer. It was underwritten before a 31% decline that none of our tools can explain, probably at much higher prices, and under a trend that has since broken. The question is whether you'd hold that size today with these gaps, and the plan itself says no above half. I'll take Neutral's version. Don't trim to half by rule, run the gap test, and if an 8% drop to the mid-220s isn't tolerable, that's your trim, using limit sells in the 246 to 250 zone rather than a market order.

Where I still disagree is your new ladder, because I think it's worse than the trader's plan.

You say the blended entry at 238.85 cuts risk from 11.80 to 9.65 points. That's per share, on a position twice as large. A third at 241 risks about 3.9 units of a standard allocation to the 229.20 stop. Two thirds blended risks about 6.4, which is roughly 64% more dollar risk. The R-multiples improve because the second tranche sits only 7.5 points above the stop, about 1.7 ATR. You're buying closer to the stop, which makes it more likely to be hit.

That second tranche is also only about 4.4 points above your own cut-half trigger at 232.28. The blended entry is only about 1.5 ATR above that trigger. After an earnings print, a one-ATR wobble is normal, and the only big day we know about in this dataset was 4.8% on 9/23. So you'd probably buy at 236.70 and then be cut in half days later, or you'd override the rule. Either way, the ladder pays for the whipsaw.

The "roughly 4% loss" is also a best case. Your exits are daily-close triggers, so you act after the close at a price you don't control. A 4.8% day from 236.70 lands near 225, which is through 229.20 in one session. Exiting there from 238.85 costs about 1.4R, not 1R. Against a 1.9R payoff to the 257.49 shelf, the win rate you need goes from about 35% to about 42%. The 2.8R and 4R targets also run through 246, 250, 257 and the weekly stop, and the report says none of those levels has been validated. The 200 SMA only becomes a target if the whole trend changes.

There's a selection problem too. After a clean print, your 241 and 236.70 bids fill mainly when the market is selling the clean print. That's a weak tape, and it's the one place the weekly and monthly downtrends are most likely to reassert themselves. You said my pullback argument supports the entry. It supports one bid at 241 after the print, not averaging down a second time into a drop the market hasn't explained.

On "the stock has paid eight turns for deceleration," that assumes 28x in February was a fair starting point. The report has no multiple history, and 28x came at the top of a run from 287 to 334. You can't say the market has priced in a story when our own tools say they can't explain the decline. Q2 revenue slowed to 3.7%, the headlines say U.S. comps are softer, and the PEG you conceded is 2.57. An unexplained 31% drop is a risk, not a cushion.

On the cap, I'm moving toward Neutral. I'd lift from half to standard when the checks are clean and price closes above 257.49. Clean information is necessary, but it doesn't mean the market accepted it. Your information-only lift would take you to full size on the same day the weekly and monthly trends are still down. I'd also keep the first add at a quarter if any check is incomplete, and give each later tranche its own stop.

Neutral, I mostly agree with you, but I'd drop the dividend hook as a reason to hold. It's a headline-only item. On the report's own derived $7.67 annual dividend, a quarterly payout is about $1.92, roughly 0.8% of price, against a 4.8% single-day move we've already seen. It's not a reason to hold a position you'd otherwise trim.

So I still back Hold. Add nothing before the print, test your existing size against a gap, and after the print use one bid at 241 or below, sized at a quarter to a third, with no averaging down at 236.70. Only give up the half cap on clean checks plus a close above 257.49. If I'm wrong, I miss the first few points of a repair. If the ladder is wrong, you've doubled the dollar risk in a downtrend, with stops that earnings-week noise can trip. Conservative Analyst: Aggressive, Neutral, we're close enough that I'll concede what's settled and spend my time on what's left.

I'm fine with the 236.70 bid being gone, with the gap test replacing any trim-to-half rule, and with a third instead of a quarter if every check comes back complete. One correction to how we've all been framing the half cap: debt, interest coverage and the FCF reconciliation aren't waiting on the print. The June-quarter 10-Q has the debt schedule, so we can close those gaps today. What only the print and the tape can answer is outcome uncertainty, not a data gap. The cap and the staircase are guarding against different things, and the staircase is what handles the second kind.

My bigger problem is the "clean" test, because it barely discriminates. Operating margin has sat between 45 and 47 percent the whole way down, so a stock that fell 31% already passed that check. "No guidance cut" and "nothing ugly on debt" don't address why the stock fell, which is deceleration. Q3 2025 EPS was $3.18, so 6% growth is about $3.37 and the roughly 11.7% implied by forward EPS is about $3.55. Revenue growing 3.7% off $7.08B is about $7.34B. That is my arithmetic, not consensus, which we don't have. But a print at the current trend rate passes your clean test and still forces forward estimates down, which is the 18.8x scenario I raised at the start. "Clean" has to include EPS and U.S. comps relative to the growth the forward multiple needs.

Aggressive, "real asymmetry" in the first tranche doesn't survive your own supply argument. You said 250 to 257 is where trapped holders want out. Then the 1.4R and 2.1R figures use 257.49 and 265.86 as targets, straight through that supply. From 241 to the first shelf at 250.18 is about 9 points against 11.8 of risk, roughly 0.8R. The better payoffs only arrive after the shelf clears, and that confirmation is exactly what the staircase waits for. I'd go to a third only on a fully complete check list, and a quarter otherwise. Also, a daily close above 232.28 isn't a gate for lifting the cap. It's the same level where the plan cuts the position in half. It shows the stop hasn't been hit, not that the market accepted anything.

Neutral, I back the staircase with two amendments. First, cap open risk instead of arguing over notional ceilings. Each add on strength should be paid for by trailing the earlier stops up, so the total dollar risk to stops never exceeds what the first tranche carried. Stops should also sit at least about two ATR away, roughly 8 to 9 points, because I've already shown how earnings-week noise trips tighter ones. Second, a single close above 257.49 is cheap, since it's only a pre-breakdown local peak. I'd want it to hold a retest, as you already require at 250.18, before the ceiling reaches standard. With the weekly and monthly trends still down, standard stays the maximum.

Finally, I want to challenge a premise all three of us have shared: that the Q3 print is still ahead. The only support is a fundamentals tool that says Q3 is "not in my data," and our reports admit there's no earnings date. Statement data often lags a report, and the sentiment report even includes a retail post about MCD after an "earnings crash." I recall MCD reporting Q3 in the first week of October last year, but that's memory, no better than your late-October recollection, Aggressive. The 11.4M-share reversal on 10/8 might be the market digesting results already. I'm not claiming it is. I'm saying the whole plan rests on it, and a calendar lookup settles it in a minute. If the print is behind us, the debate changes. We'd read the actual release, and the tape has already given its verdict.

The same goes for 9/23. It's the biggest unexplained day in the data, and nobody has put it on the to-do list. Pull the news for 9/22 to 9/24 and see whether peers and the index fell with it. If it was company-specific, I want to know before adding a dollar.

And Aggressive, if the print is still weeks away, I wouldn't let a pullback to the 10 EMA tempt a pre-print bid. A pullback to 241 is the daily TD 9 doing what it was expected to do, not new information.

So I'm still at Hold. Do the homework today, add nothing blind, size the first tranche to what's actually been verified, and let price and trailing stops pay for every add after that. If I'm wrong, we miss a few points of repair. If the front-loaded version is wrong, we've bought into the supply zone with a gap-prone stop. Conservative Analyst: Aggressive, Neutral, we're close now, so I'll take the concessions first and then the three places I still see exposure.

Aggressive, thank you for dropping valuation as the cushion. At roughly 19.3x on a run-rate year, nobody can call it a margin of safety, and it makes your case more honest. Neutral, your "no worse than run rate" definition of clean is what I was reaching for. I'd also pin the thresholds down in numbers before the print, so nobody reads them afterward. Off last year's Q3 base, a run-rate print is roughly $3.37 of EPS and roughly $7.34B of revenue. Those are my arithmetic, not consensus, since we don't have any. The $3.55 that the forward multiple implies is the real bar for "above run rate." A third should require clearing both numbers clearly, not just matching them.

My first remaining disagreement is timing. Aggressive wants the first tranche in on the day the checks are complete, sized to the reaction. But part of "clean" is that the stock holds 232.28 and the 10 EMA zone after the reaction, and you can't judge that on the same day. A limit bid at the 10 EMA also fills on weakness, which on a post-print day is the follow-through you least want to catch. If the print is still ahead, this doesn't arise, because we're flat anyway. If it's behind us, the reaction is already in the tape and we can read it today, once the 10/21 bar is final. So the rule I'd use is to wait for the first full post-print session to close and bid after that. That costs about one day.

The second is the cost of being wrong. Aggressive is right that a third stopped at 229.20 loses about 1.6% of a standard allocation. That's modest per attempt. But every rally in this decline has made a lower high, and the tool describes three waves down with failed bounces in between. Cheap attempts that keep failing still add up. So I'd add one rule that replaces gates rather than adding more. If the first tranche gets stopped out, there's no re-entry until price has closed above 250.18 and held a retest. One cheap attempt is fine, but the plan shouldn't average into repeated ones.

The third is how we size. Everything we've said is in fractions of a standard allocation, and we don't know the caller's book. So a quarter or a third is a ceiling for the first tranche, and the gap test decides whether it's smaller. A beta of 0.45 shouldn't relax that. The stock lost 31% with that beta, so beta says little about whatever hit it. That's also why the 9/22 to 9/24 check against peers and the index matters. I'd also measure the two-ATR floor off the post-reaction ATR, not today's 4.31. ATR has compressed since the 9/24 peak of 5.12, and I'd expect an earnings reaction to widen it. That's an expectation, not something in the data.

Aggressive worries the plan has so many gates it can't make money. I don't think that's right. Most of the gates are one-time homework that can be done today: the print date, the 10-Q debt and coverage, the FCF reconciliation, and the 9/23 news. The live conditions on the entry itself are only two, a print at least at run rate and the stock holding 232.28 and the 10 EMA zone. The price gates apply only to the upsizing, and that's the right place for them. The plan can make money and it can lose it. It just can't lose a lot on one unexamined premise.

On the premise, I'm glad we all agree the print date goes first. The Zacks and Simply Wall St. headlines about softer U.S. comps read as consistent with either a preview or a post-print recap, so they don't settle it. Neither does the fundamentals tool. Look it up.

Neutral, your staircase has my support, including shrinking an add instead of tightening its stop. The structure is a first tranche capped by the gap test, a second only after 250.18 holds a retest, a third only after 257.49 holds a retest, and standard as the maximum. Open risk never exceeds the first tranche's budget. If I'm wrong, we miss a few points of repair. If the front-loaded version is wrong, it's wrong in the stock that has failed every bounce since February. I'm still at Hold. Conservative Analyst: Aggressive, Neutral, we're close enough that I'll skip the victory laps and say what I'm taking and what I'm not.

I take the $3.55 point. Aggressive's math holds. If $13.75 is calendar 2026 and Q4 lands near the derived $3.03, the back half needs about 23% growth, so no realistic Q3 print clears that bar. I read that as one more reason 17.8x was never a cushion, but as a hard gate you're both right. Use $3.37 and $7.34B to screen out a bad print and let the reaction be the veto. A quarter at run rate is fine, and so is a third when EPS and U.S. comps are clearly better than Q2. I also take Aggressive's point that the confirmed tranches need wider stops. That's already our rule: a wider stop means a smaller position, never a tighter stop.

Now the places I'm not moved.

The reaction test is too loose as worded. "Holds 232.28" is a low bar. Say the print is mildly disappointing and the first session closes at 236. That's almost 4% below today, above 232.28, and below a 10 EMA that will be around 240. A bid "at or under the post-reaction 10 EMA" is already marketable at that price, so you'd be buying the day after a negative reaction and calling it a pullback. I'd define a hold as a close back above the 10 EMA. A close between 232.28 and the 10 EMA is a failed reaction, and you stand aside.

The "one-shot, so make it real" argument runs backwards. A lockout after a stop-out limits losses. It isn't a reason to size up the attempt that might trigger it. The cost Aggressive describes mostly doesn't exist either. If the first tranche is right, the lock never bites, because the stock is going through 250.18 and the next step arrives. The lock only costs you in a stopped-out-then-rips whipsaw, which is the case it's meant to prevent. I'm fine with a third on the above-run-rate branch because the information is better, not because of the lock. The 1.6% figure is also a fill-at-the-stop number. With daily-close exits and a gap through 229.20, a third is closer to 2%, and the gap test has to run on the whole position after the add, not on the tranche alone. Someone already at half a standard allocation who adds a third has a different gap loss than the tranche suggests.

There's also a design flaw nobody has caught. The account doesn't know which shares are legacy and which are new. Neutral wants a staged cut for old exposure and a single stop for new tranches, but a position has one average cost and one risk number. I'd run one exit rule on the whole position and size each add so total open risk to that exit stays inside the budget.

On trimming, we all said that if the gap test fails you sell the excess with limits at 246 to 250. A limit above the market can sit unfilled while the exposure you called intolerable stays on. Put a deadline on it. If the excess hasn't sold by the last session before the print, sell it anyway. Giving up a point or two on the excess is cheap next to an 8% gap, and it's one more reason the date lookup comes first.

Neutral called this a tactical bounce trade and not a value thesis, and I agree, but nobody has said when it's over. If a first tranche is in and neither a 250.18 reclaim with a retest nor the stop has happened within three or four weeks, I'd cut it back. That window is my judgment, not something in the data. A counter-trend rally that can't clear the 50 SMA while the 200 SMA falls about 7.5 points a month is failing on time even if price hasn't tripped a stop.

On the cost of waiting, Aggressive was honest that we give up some of the move, and I accept that price. But the first tranche is now the same in all our plans. Nobody buys the gap, and nobody has a position if the stock never pulls back. The extra points only touch the later adds, which are small sleeves. That's well under a percent of a standard allocation, against a stop-out or a gap loss on the first tranche of roughly 1.6% to 2%.

On the date, if the print turns out to be behind us, the fundamentals report is a quarter stale. Forward EPS, the TTM figures and the 11.7% implied growth would all need redoing before anyone sizes anything.

So I'm still at Hold. Add nothing and place no bids before the print. Bid only after a post-reaction close back above the 10 EMA. Run one exit on the whole position, put a deadline on any trim, and put a time limit on the trade.

Neutral Analyst¶

Neutral Analyst: I agree with the Hold, but I think you're each arguing against a plan that isn't quite the one on the table, and each of you leans hardest on the weakest numbers.

You both did the same thing with the R-multiples. The plan doesn't buy at 245.28, and if you're flat it places no resting bid at 241 before the print. So Aggressive's 1.4R, 2.1R and 3.5R are measured from an entry that only exists after Q3, and Conservative's 0.8R, 1.3R and 2.3R are measured from a price nobody proposes to buy. Both calculations are arithmetically right and mostly beside the point. The real question is what happens after the print, and that's where the plan is thin.

Aggressive, "asymmetry" isn't established by the 31% drop against 6.3% EPS growth. The same fact says the market is pricing deceleration: Q2 revenue slowed to 3.7% from 9.4%, and Q2 EPS grew 5.7% against the roughly 11.7% embedded in forward EPS. Our tools can't explain the 9/23 flush, so "forced selling meeting real buyers" is a story laid over an unexplained 16.6M-share day. Conservative's "the market stopped believing the growth" is also a story, just a gloomier one.

"Crowded bad news" doesn't hold up either. A 5.2 out of 10 at low confidence, with Reddit missing and 9 tagged posts out of 30, isn't a pessimism reading. It's close to no reading. And your plan to go to full allocation on a "mixed or better" print skips a point you made yourself. The print closes information gaps, but it doesn't turn the weekly or monthly trend, and a mixed print is exactly when forward estimates get trimmed.

Conservative, I like your gap-sizing point, but some of your tightening goes too far. The plan already trims anything above a standard allocation. Capping new money while blind is different from forcing existing exposure down to half. A standard allocation is already the risk budget. RSI has reset from 21.78 to 55, OBV has recovered, and we're 6% off the low. Trimming below standard because a daily indicator is stretched means trading a signal that may rest on a partial bar. The 10/21 volume of 2.57M is well under the usual 4 to 6M, so the TD 9 and the +1.77 z-score are provisional.

Holding the half cap until the weekly SuperTrend flips at 265.86 is also a gate that opens only after most of the repair is done, which is Aggressive's best point. Most of the gaps the plan cites, like the Q3 date, debt, coverage and the FCF reconciliation, get closed by the release and filing, not by a weekly trend flip. Your FCF critique is also partly misdirected. The mismatch is between the TTM figure and the summed quarters. The 18% H1 growth compares four reported quarters directly, so it's firmer than the 1.15x coverage, which leans on TTM FCF and an approximated dividend. Both say the same thing: cash flow is growing and the cushion is thin.

You both also treat the forward multiple as precise, with 17.8x on one side and 18.8x on the other. The report doesn't say what period the $13.75 covers. If it's calendar 2026, the second half would need EPS growth in the low twenties, which is a big ask. So read "under 18x" as soft. Similarly, "no cuts is consensus" and "no cuts can't rescue the multiple" both assume a stable 97%, but we only have a snapshot and no FRED data.

Here is what I'd change. Before the print, keep the plan. Add nothing and place no bids. If you're above standard, trim the excess with limit sells in the 246 to 250 zone instead of at market. If you're at or below standard, hold. Then take Conservative's gap test seriously. A 4.8% unexplained drop happened a month ago, so assume the reaction can run through 232.28 and 229.20 in one session. Make sure a drop to the mid-220s, about 8%, is tolerable. If it isn't, that's your sizing answer.

After the print, define "mixed or better" before you see it: margin near 46 to 47%, no guidance cut, and nothing ugly on debt or coverage in the filing. Then judge the price reaction, not just the headline. If the daily SuperTrend at 232.28 holds and the checks are clean, add a third at 241 or below, as the plan says. If the checks are incomplete, add a quarter. That difference isn't worth fighting over.

Further adds should be earned by price, not by the calendar. I'd add the next tranche only on closes above the 50 SMA at 250.18 that hold on a retest, and I'd set its stop against where it's bought instead of inheriting 229.20. That answers Conservative's 26-points-versus-11 problem. I wouldn't chase a gap into the 250 to 257 shelf, and I wouldn't feel bad about missing it.

For the ceiling, I'd stay at standard until the weekly trend turns, never above. But I'd let the cap move from half to standard when the information gaps are closed and price closes above 257.49, rather than waiting for 265.86. The Dec. 1 dividend hook is a low-confidence, headline-only tailwind that neither of you used. It's one more reason not to sell below standard just to feel safer.

So I'm still at Hold. Aggressive's version puts you at full size in a falling-200-day stock on a print that fixes information, not trend. Conservative's version risks a permanent half cap on a quality franchise. A staircase gives up the first few percent of a gap and the last stretch of the repair, but it keeps you from being oversized in either mistake. Neutral Analyst: You've both moved toward the middle, so the real disagreement is down to two things: what earns the second tranche, and what lifts the cap. First, a few corrections on each side.

Conservative is right on the ladder arithmetic. Risk per share dropping from 11.80 to 9.65 is just averaging down. If both thirds fill, dollar risk goes up about 64%. The 236.70 bid also sits roughly one ATR above the 232.28 cut-half trigger, so the add and the trim are almost the same event. A rule set that buys at 236.70 and sells half at 232.28 is built to trade against itself. Aggressive, I'd drop that bid.

Conservative, two things in your rebuttal go too far. You charge the ladder 1.4R for a gap through the stop but never credit winners for gapping through targets. Fat tails cut both ways, and the lesson is that stop-based R math is soft, which is why sizing to the gapped loss is the real control. Also, "an unexplained 31% drop is a risk, not a cushion" is as much a story as "the stock has paid eight turns." Our tools can't explain the decline, but that tells us about the tools, not about the market. The honest position is uncertainty, and the print resolves part of it. That is the case for waiting, not for either narrative.

On the eight turns, Aggressive, 28x is a February-peak number. A year ago the stock was around 287. With trailing EPS somewhere near 11.5 to 11.7, which is my rough estimate since the report has no multiple history, that was a mid-20s multiple. The compression is real but closer to four or five turns, which shrinks the "already paid for deceleration" argument. A mixed print has less to take away than it did in February, but that isn't enough to pre-commit to scaling.

Neither of you has addressed that the 241 and 236.70 levels are computed from today's chart. After a print they may be irrelevant. If the stock gaps to 258, you don't chase. If it closes under 232.28, you don't add at all. If it lands near 238, the 10 EMA and the daily SuperTrend will have moved a little, so anchor the bid to the post-reaction structure, not to numbers from this week.

On the cap, the practical disagreement is narrow. A first tranche of a quarter to a third is under the half cap anyway. The cap only bites on the second tranche, so the question is what earns it. Conservative is right that averaging down into a post-print sell-off isn't it. That is the weak tape where the weekly and monthly downtrends are most likely to reassert. Aggressive is right that if the only gate is a close above 257.49, most of the build happens on the supply shelf.

So I'd split it by price steps. Take a first tranche near the post-reaction 10 EMA if the checks are clean and 232.28 holds. If it never fills and the stock reclaims 250.18 and holds a retest, a quarter can start there instead, so a clean breakout isn't a total miss. Once the first tranche is validated by a close above 250.18, the ceiling can rise to about two-thirds of standard. Standard comes after a close above 257.49 with the checks still clean.

Each of those adds carries its own stop under its own retest low, not an inherited 229.20. That handles the 26-points-versus-11 problem. The payoff there is modest, about 1.5R to the weekly stop and under 1R to the 257 shelf, so you're buying confirmation, not payoff. I accept that this gives up the first few points of a repair, and that is the cost of the staircase.

Aggressive's inference on the weekly SuperTrend is also sound. In a downtrend it only ratchets down, so 265.86 drifts lower over time. That is why I'd never use the weekly flip as the gate, and I'm glad Conservative dropped it.

On existing exposure, we've converged. Aggressive, "underwritten earlier" is weak because it's sunk-cost reasoning. But I'd also skip any rule to trim to half. Ask whether an 8% gap to the mid-220s is tolerable at your size. If it isn't, trim the excess with limit sells in the 246 to 250 zone, not at market. If it is, hold.

Conservative, you're right about the dividend. About $1.92 a quarter on 245 is 0.8%, resting on a headline-only item, so I'll drop it as a reason to hold anything.

Before the print, define "clean" in advance. I'd use operating margin near 46 to 47%, no guidance cut, nothing ugly on debt, coverage or the financing outflow, and U.S. comps not materially worse than the headlines imply. Look up the Q3 date first. The plan can't say "before the print" without knowing when it is.

So I'm still at Hold. Aggressive's ladder fights its own stop and leans on a gate that opens whenever the data does, while Conservative's cap risks staying shut until the repair is mostly done. The staircase keeps you from being oversized in either mistake. It costs some upside, and it keeps a bad print or a failed bounce from being a large loss. Neutral Analyst: We've converged on most of this, so I'll say what's settled and spend the rest of my time on the open points. Nobody adds or places bids before the print. Existing exposure gets the gap test, meaning you ask whether an 8% drop to the mid-220s is tolerable at your size, and you trim any excess with limit sells in the 246 to 250 zone. The 236.70 bid is gone. The dividend hook is gone. Every tranche carries its own stop, and a single close above a level isn't enough without a retest. Standard allocation is the ceiling until the weekly trend changes.

Conservative, your best contribution is the premise check, and I'd put it first on the list. The fundamentals report says Q3 isn't reported, but it's the same tool that says it has no news, no guidance and no earnings date. It can't tell "not reported" from "not ingested." The sentiment report even has a retail post about a stock that rose after an earnings crash. I don't trust my memory on the date either. It has moved around a lot from year to year, which is why neither your recollection nor Aggressive's is worth anything. Look it up. I'd also take your split of the data gaps. Debt, coverage and the FCF reconciliation are 10-Q homework we can do today, so the half cap lifts when that work comes back clean, not when price or the print says so. The plan also survives either answer on the date. If the print is behind us, the same rules apply: read the release, then bid near the post-reaction 10 EMA, and don't chase 245 with a completed daily 9 on a bar that may be partial.

The 9/23 point matters because the answer changes what "clean" means. If peers and the index fell that day, it looks like de-risking. If it was company-specific, the checklist has to address that specific thing.

You're also right that my "clean" test barely discriminates. Margin has been 45 to 47% all the way down. But your arithmetic shows something else. We have no consensus and don't know what period the $13.75 covers, so we can't call any print a beat or a miss. A print at Q2's trend rate would pass every check I listed and still trim estimates. So I'd define clean as "no worse than the run rate." That means EPS growth around 5 to 6% or better, revenue growth around 3 to 4% or better, U.S. comps positive, no guidance cut, and a stock that holds 232.28 and the 10 EMA zone after the reaction. A print that only meets that earns the quarter. A third needs a result above the run rate and a reaction that holds. That ends the quarter-versus-third argument without anyone having to be right about it.

Aggressive, I'd push back on "real asymmetry in the first tranche." From 241 with 11.8 of risk, the first shelf at 250.18 is about 0.8R, and 257.49 and 265.86 are 1.4R and 2.1R, all through supply that nobody has validated. That's a modest edge that depends on the shelf clearing. It argues for a measured first tranche, not a front-loaded one. And a close above 232.28 can't be the gate to lift the cap, because that's the level where you cut the position in half. It shows only that your stop hasn't been hit.

You're right on one point, though. Confirmation isn't free, and it isn't pure cost either. A later tranche bought at 251 with a stop around 243 has a similar R to the weekly stop, but a higher chance of working because the shelf has already cleared. You pay in entry price and get paid in probability.

Conservative, I like your open-risk cap and the roughly two-ATR minimum stop, with one condition. If trailing the earlier stops up to pay for an add pushes them inside two ATR, you've rebuilt the whipsaw you warned about. So when the budget is tight, shrink the add and don't tighten the stop. That also explains why later tranches come out smaller without anyone legislating it. And size to the gapped loss, not the stop distance, since the exits are daily closes.

Here's my adjusted plan:

Today: look up the Q3 date, read the June 10-Q for debt and coverage, reconcile the FCF, check 9/22 to 9/24 news against peers, and re-run the daily readings once the 10/21 bar is final.
Before the print: add nothing and place no bids.
After clean checks: a first tranche of a quarter to a third, bid at or under the post-reaction 10 EMA, with a stop at least two ATR away.
After the first tranche is in: the next tranche waits for a close above 250.18 that holds a retest, and the one after that for 257.49 with its own retest. Total open risk stays within the first tranche's budget, and standard remains the maximum.

If you add that up, Aggressive's risk is being oversized in a falling-200-day stock on a print that fixes information, not trend. Conservative's risk is a permanent cap that opens only after most of the repair is done. The staircase gives up the first few points and the last stretch, and I think that's the right price for not being badly wrong in either direction. I'm still at Hold. Neutral Analyst: We're down to one trading day, a re-entry rule, and a few soft spots, so I'll go through those.

First, timing. Aggressive wants the first tranche in the day the checks come back, and Conservative wants the first full post-print session to close. If the print is already behind us, there's no dispute. The reaction is in the tape, you read it once the 10/21 bar is final, and you can bid that day. If the print is still ahead, I side with Conservative, and it costs one day. A bid at the 10 EMA on reaction day fills on the way down, before you know whether 232.28 holds on a close, and the 10 EMA and daily SuperTrend haven't updated to the new structure. Aggressive, you said you'd rather own the cheap tranche first and the confirmed one second. One close of waiting still gets you that. It's a long way from several closes.

Conservative, I'd soften your EPS thresholds. $3.37 and $3.55 are good sanity numbers, but they come from last year's base and your arithmetic, not consensus, and the market grades against consensus, which none of us has. A print can clear $3.55 and sell off, or land at $3.37 and rally, depending on what was priced in. So use the numbers to screen out obviously bad prints and let the reaction be the real veto. If the stock holds 232.28 and the 10 EMA zone after the print, the market is telling you the number was acceptable. A third then needs a result above run rate and a reaction that holds, without a hard "clearly above both numbers" test.

I'd also drop "failed every bounce since February" as a premise. It describes the past, and whether this bounce ends as a lower high is the open question. This is the first bounce in our data where RSI reset from 21.78 to 55 and OBV is back above its 9/22 level, though the report doesn't show earlier bounces on those measures, so I can't compare. That doesn't make it a winner. 250.18 and 257.49 will decide that, but it means you can't assume the answer.

I do like your re-entry rule. If a tranche gets stopped out, the stock is probably in the mid-220s, so 250.18 is about 10% away. The rule really means no re-entry until the regime changes. I'm fine with that, but say so plainly, so nobody treats it as a timeout and sneaks back in at 232.

Here's a design problem neither of you flagged. The plan cuts half at 232.28 and exits at 229.20. Those are 3.1 points apart, less than one ATR of 4.31. For a fresh tranche that's one decision, not two. If a close below 232.28 happens, a close below 229.20 is likely within days, and in the gap case Conservative described, both trigger in one session. So for new money I'd use a single exit, anchored to the post-reaction structure and at least two post-reaction ATRs from the entry, with the tranche sized off that distance. A wider stop means a smaller position, never a tighter stop. The staged cut makes sense for legacy exposure, not for a tranche you just bought. The daily SuperTrend also trails, so 232.28 is today's number. That's my inference from how the indicator works, and it's another reason to recompute after the reaction.

Aggressive, one correction on your cost-of-confirmation math. A later tranche near 251 doesn't just cost 10 points more in entry price, because its stop moves up too. A stop around 243 is about 8 points of risk, less than the 11.8 on the first tranche, and the payoff to the weekly stop is maybe 1.5 to 2R. You pay in lost drift, not in worse risk per share. So the confirmed tranche is cheaper than you made it sound, and that's the case for the staircase over the ladder. Your "too many gates" worry is fair, but the plan reduces to three live questions. Which branch are we on, the print ahead or behind? Is my existing size survivable at an 8% gap? Did the first post-reaction close hold 232.28 with the checks clean? The rest is one-time homework or upsizing, and only the upsizing needs price gates.

On valuation, 19.3x on a run-rate year still leans on a derived Q4 EPS of about $3.03. Call it 19 to 20x for a roughly 6% grower with a 3.1% yield. That's fair, neither cheap nor expensive. So this is a tactical bounce trade, not a value thesis, and it should be sized and held that way. The dividend doesn't pay you for waiting on a two-week trade.

One last amendment to the trader's text. Its sizing rules are in allocation units, like "trim to standard" and "half of standard," and those depend on a book we can't see. The gap test is in loss units: if the stock drops 8% to the mid-220s, can you live with it at your size? That test applies to whoever is reading this, so it should replace "trim to standard." If the answer is no, trim the excess with limit sells in the 246 to 250 zone.

So here's where I land. Add nothing before the print, do the homework today, and bid only after the first full post-print close holds. Size the first tranche at a quarter to a third, capped by the gap test, with one exit and no re-entry after a stop-out until 250.18 is reclaimed and retested. Each later tranche needs its own retest and its own stop, and the total never goes above standard until the higher timeframes change. We give up a few points of the repair. In exchange we avoid being oversized in either mistake: buying a stretched daily 9 on a bar that may be partial, or sitting out a quality franchise behind a gate that opens too late. I'm still at Hold. Neutral Analyst: Most of what's left is small, so I'll concede quickly and spend my time on the three places where I think each of you is still off.

Conservative is right that 232.28 is a stop level, not a confirmation level. If a print disappoints and the first session closes at 236, below a 10 EMA near 240, a bid at the 10 EMA is just buying a negative reaction and calling it a pullback. I'll take the close back above the 10 EMA. It's trivially met today, with 245 against 241, so it only bites when something has gone wrong, which is what a filter should do. He's also right that the lockout is a reason to keep the first attempt small, not big. Aggressive, "make it a real one" cuts against you. If the first shot is the only shot, you want it to be the best-informed shot, and that argues for waiting one close.

Aggressive is right that a confirmed tranche near 251 should be smaller, with the stop at least two ATR away. But "four points of a ten-point move" counts reward without risk. From 241 with 11.8 of risk to the 265.86 weekly stop, you get about 2.1R. From 251 with about 8.6 of risk, two ATR at today's 4.31, you get about 1.7R. The cost of confirmation is closer to 0.4R than to 40% of the move. And the 241 bid has to survive the 246 to 257 supply shelf on its way up, while the 251 tranche has already cleared 250.18.

Conservative, three of your points need work. You're right that the account can't tell legacy shares from new ones, and the 3.1-point gap between the cut-half and exit triggers makes the staged cut a fiction anyway. So I'll drop my split and run one exit on the whole position. Measure the risk from the current price, not from cost, because a holder with a 300 cost basis has the same forward risk as new money. From 245 to 229.20 is about 6.5% of the position before any gap slippage. That also undercuts your lot-identity objection to the time stop. You know how many shares you added, so the time stop is simply selling back to your pre-add share count.

I'd accept the time stop with two caveats. It's a verdict on the tactical tranche, not on the franchise, because bases usually take months and four weeks is a discipline, not a prediction. And "failing on time" because the 200 SMA is falling is one-sided. That average dropped about 7.5 points in a month, which shrinks the gap price has to cover even if price goes nowhere. It doesn't make the setup bullish, but it means the clock doesn't only run against us. I'd also accept your deadline on the trim, anchored to the last session before the print rather than to an arbitrary date.

Aggressive, you said the date "tells us how long we wait, not what we do." I disagree. If the print is ahead, we're flat and waiting. If it's behind us, the stock is already at 245 at the top of the band with a completed daily 9, the fundamentals file is a quarter stale, and the live question is a pullback bid at the 10 EMA after reading the actual release. Nothing proves it's behind us, but the pieces fit that story better than I'd assumed. The 10/8 reversal on 11.4M shares, a retail post about a stock rising "after an earnings crash," and headlines like "Softer U.S. Sales" read more like recaps than previews. So I'd write the plan for both branches and treat the lookup as the first task, not a footnote.

Your "too many gates" worry is answered by the three live questions. Which branch are we on? Is existing size survivable at an 8% gap, meaning the mid-220s? Did the first post-reaction close get back above the 10 EMA with the checks clean? The rest is homework done once, or upsizing rules that only matter if the first tranche works.

On valuation, nobody should use it as the argument. At 19 to 20x for a roughly 6% grower, MCD is fairly priced. This is a tactical trade, and the dividend doesn't pay you for it.

So I'm still at Hold, with these adjustments to the trader's plan:

Today: look up the Q3 date, check 9/22 to 9/24 news against peers and the index, read the 10-Q for debt and coverage, reconcile the FCF figure, and re-run the daily readings once the 10/21 bar is final.
Existing exposure: run the gap test in loss units to a single exit. Trim any excess with limit sells at 246 to 250, with a deadline of the last session before the print.
Before the print: add nothing and place no bids.
First tranche: after the checks are clean and a post-reaction close back above the 10 EMA, bid near the 10 EMA. Size it at a quarter if the print matches run rate and a third if it beats it, always capped by the gap test. Use one stop at structure, at least two post-reaction ATR away.
Later tranches: each needs a close above 250.18, then 257.49, each holding a retest. Each should be smaller, open risk should never exceed the first tranche's budget, and standard stays the ceiling until the weekly trend turns.
Exits: after a stop-out, no new money until 250.18 is reclaimed and retested. If a first tranche sits for three or four weeks with no reclaim, sell back to your pre-add size.

The trader's 241 and 229.20 are this week's chart, so recompute them after the reaction. The plan gives up the first few points of a repair and some of the last. In exchange it avoids two mistakes: sizing up a stretched daily 9 on a possibly partial bar, and sitting out a decent franchise behind a gate that opens too late.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Hold

Executive Summary: Hold MCD at 245.28. Add nothing and place no resting bids until the Q3 2026 print date is confirmed and the results are read. Test existing size against an 8% gap to roughly 225.7; if that loss is not tolerable, sell the excess with limit orders at 246-250, and sell at market if those have not filled by the last session before the print. After a run-rate-or-better print, and only after a full post-reaction session closes back above the 10 EMA, open a first tranche of ¼ to ⅓ of a standard allocation near the 10 EMA, with one stop at least 2 post-reaction ATR away (today about 229.20, which is 2.7 ATR from 241). Further adds come only on closes above 250.18, then 257.49, each holding a retest; never exceed a standard allocation while the weekly trend is down, and exit on a daily close below 229.20, negative U.S. comps or a guidance cut.

Investment Thesis: Why Hold: The three risk analysts started far apart and ended on Hold with nearly identical rules. That agreement came from testing each other's evidence, not from splitting the difference. The deciding facts point both ways, and the variable that settles the question, Q3 U.S. comps and guidance, is unseen. That is the 'too thin to call' case, so Hold is not a default here.

Why not Overweight: The Aggressive analyst's case for buying ahead of confirmation lost on the merits, and he withdrew most of it. - He dropped valuation as a cushion. If the 13.75 forward EPS is calendar 2026, H2 needs about 23% growth. Run-rate 2026 EPS is about 12.70, which is about 19.3x, not 17.8x. - He withdrew 'crowded bad news'. The sentiment score is 5.2/10 at low confidence with only 9 of 30 posts tagged. - He conceded the ladder. A second bid at 236.70 raised dollar risk about 64% and sat about 1 ATR above the 232.28 cut trigger. - His R-multiples ran through untested supply at 246.41, 250.18 and 257.49. From 241, the first shelf pays only about 0.8R. - The higher timeframes are still down: weekly SuperTrend stop 265.86, monthly 306.43, and a falling 200 SMA at 282.01 with the 50 SMA below it. - Q2 slowed to revenue +3.7%, operating income +3.3% and margin 47.0% versus 47.2%.

Why not Underweight: The Conservative analyst's tightening also lost where it went too far, and he conceded those points. - He gave up the trim-to-half rule and the half cap tied to a weekly SuperTrend flip. - No exit trigger has fired. Price is 6.2% above the 230.88 closing low and above the 229.20 intraday low, and there is no negative comp data and no guidance cut. - H1 2026 revenue grew 6.4%, operating income 7.0% and EPS 6.3%. Operating margin is about 47%, TTM FCF is 6.26B, beta is 0.45, and the equity deficit has narrowed from -5.18B to -1.02B. - On the tape, RSI reset from 21.78 to 55.6 and OBV is back above its 9/22 level while price has recovered about 74% of the drop. - The bearish short-term signals (daily TD 9, +1.77 z-score) rest on a 10/21 bar with 2.57M shares against a normal 4-6M, so they may be partial.

Adopted rules, from the strongest late-round points: - Conservative: the reaction test is a close back above the post-reaction 10 EMA, not merely holding 232.28. Run one exit on the whole position, because cut-half at 232.28 and exit at 229.20 are 3.1 points apart, less than 1 ATR of 4.31. Put a deadline on any trim, and limit the first tranche to 3-4 weeks. - Neutral: size in loss units rather than allocation units, since the book is unknown. Measured from today's price, 245.28 to 229.20 is 6.6% before gap slippage. A wider stop means a smaller position, never a tighter stop. After a stop-out, no re-entry until 250.18 is reclaimed and retested. - Aggressive: no hard 3.55 EPS bar. Screen with run rate, then let the market reaction be the veto. - Post-print screen, against Q3 2025 figures of revenue 7,078M, operating margin 47.4% and EPS 3.18: run rate is about 3.37 EPS and about 7.34B revenue, with positive U.S. comps and no guidance cut. A run-rate print earns ¼. An above-run-rate print with comps better than Q2 earns ⅓. Treat the RM thresholds (revenue at least 7.43B, operating income at least 3.52B, margin at least 47.4%) as the strong case.

Homework before acting: - Confirm the Q3 date. If the print is already out, these reports are a quarter stale and forward EPS must be redone. - Check 9/22-9/24 news against peers and the index. - Pull debt and interest coverage from the 10-Q. - Reconcile the 6.26B TTM FCF with the about 6.12B quarterly sum. - Re-run the daily readings once the 10/21 bar is final.

What would change the call: - Upgrade toward Overweight on an above-run-rate print, closes above 250.18 holding a retest, and ultimately a weekly close above 265.86. - Downgrade to Underweight or Sell on negative U.S. comps, a guidance cut, or a daily close below 229.20. Downside references are 226.99, then 215-222, which is 17x on 12.63-13.05.

Price target, valuation method: status-quo NTM EPS of 12.63 (RM's derivation from a status-quo Q3 of about 3.26) and trend-adjusted 12.84 (midpoint of 12.63 and 13.05), times 19.5x, the midpoint of the 19-20x range the debate judged fair for a roughly 6% grower. 12.84 x 19.5 = 250.4. That is about +2.1% from 245.28, plus a 3.1% yield, consistent with Hold. It is cross-checked by the 50 SMA at 250.18, the first overhead shelf. Confidence in the target is low, because it relies on derived EPS and no consensus or multiple history is available.

Current Price: 245.28

Price Target: 250.4

Confidence: Medium

Time Horizon: 1-3 months